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ABSTRACT
The rate of progress in improving survival of patients with solid tumors is slow due to late
stage diagnosis and poor tumor characterization processes that fail to effectively reflect
the nature of tumor before treatment or the subsequent change in its dynamics because of
treatment. Further advancement of targeted therapies relies on advancements in biomarker
research. In the context of solid tumors, bio-specimen samples such as biopsies serve as the
main source of biomarkers used in the treatment and monitoring of cancer, even though
biopsy samples are susceptible to sampling error and more importantly, are local and offer a
narrow temporal scope.
Because of its established role in cancer care and its non-invasive nature imaging offers the
potential to complement the findings of cancer biology. Over the past decade, a compelling
body of literature has emerged suggesting a more pivotal role for imaging in the diagnosis,
prognosis, and monitoring of diseases. These advances have facilitated the rise of an emerging
practice known as Radiomics: the extraction and analysis of large numbers of quantitative
features from medical images to improve disease characterization and prediction of outcome.
It has been suggested that radiomics can contribute to biomarker discovery by detecting
imaging traits that are complementary or interchangeable with other markers.
This thesis seeks further advancement of imaging biomarker discovery. This research
unfolds over two aims: I) developing a comprehensive methodological pipeline for converting
diagnostic imaging data into mineable sources of information, and II) investigating the utility
of imaging data in clinical diagnostic applications. Four validation studies were conducted
using the radiomics pipeline developed in aim I. These studies had the following goals: (1
distinguishing between benign and malignant head and neck lesions (2) differentiating benign
and malignant breast cancers, (3) predicting the status of Human Papillomavirus in head
and neck cancers, and (4) predicting neuropsychological performances as they relate to
Alzheimer’s disease progression. The long-term objective of this thesis is to improve patient
i
outcome and survival by facilitating incorporation of routine care imaging data into decision
making processes.
ii
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CONTRIBUTIONS
The main contribution of this thesis is a comprehensive methodological pipeline for
converting diagnostic images to quantitative and mineable data. Second contribution of
this thesis is several publications that demonstrated the utility of this data. Chapter 4
was published in the American Journal of Neuroradiology in 2017 [1]. Chapter 5 is pending
acceptance. Chapter 6 has been accepted by the Journal of Computed Tomography in 2017,
and chapter 7 is pending submission. My contributions to these studies are: 1) devising
technical design of the studies, 2) implementing the analysis described in “Method” sections,
both the image analysis and feature extraction processes, 3) implementing the machine
learning and part of the statistical analysis processes presented in “Methods” sections, 4)
producing the “Results” of the studies and 5) writing and editing manuscripts. I am the first
author or co-first author of these manuscripts.
The content of chapters 1 and 2 is selected from a book chapter that I wrote for the
Elsevier book titled Biomedical Texture Analysis: Fundamentals, Applications, Tools, and
Challenges Ahead. The book aims to provide technical guidance to future students and
researchers about the field of biomedical texture analysis. My chapter, chapter 8, is titled
“An Introduction to Radiomics: An Evolving Cornerstone of Precision Medicine” [2] and is
intended to introduce clinicians and future researchers to the utility of this field. All chapters
are peer-reviewed by authors of other chapters as well as the editors to ensure validity of
content and precision of language.
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Chapter 1
MOTIVATION & PROBLEM STATEMENT
Cancer is the second leading cause of death in the United States after heart disease and
is the leading cause of death in 22 states, and in Hispanic and Asian Americans [3]. Each
year, the American Cancer Society estimates the number of new cancer cases and deaths for
the current year. For 2017, 1,688,780 new cases and 600,920 cancer deaths are projected
to occur in the United States. These estimates are the equivalents of more than 4,600 new
cancer diagnoses and about 1,650 cancer deaths per day [3].
Over the past 3 decades, the 5-year relative survival rate for all cancers combined has
increased >20% as a result of advances in early detections and improved treatments [3].
However, the progress in cancer care including the decline in number of incidences and
increase in survival rate, has had almost no effect on cost of care. Cost of cancer care
increases annually by a 2% rise of cost in the initial and last phases of care, for a total of
174$ billion for projected cost in 2020. This estimate represents a 39% increase from 2010 [4].
The rate of progress in improving patient survival for some cancers has been remarkable.
Hematopoietic and lymphoid malignancies for instance have experienced an improvement of 5-
year relative survival rate of 71% for acute lymphocytic leukemia and 66% for chronic myeloid
leukemia [3]. For solid tumors, the steady increase in survival rate for most cancers has been
much slower (i.e. 18% and 8% for lung and pancreatic cancer). The slower rate of progress
for solid tumors has been linked to late stage diagnosis and poor tumor characterization
processes that do not characterize the nature of these tumors effectively or do not reflect the
aggressive behavior of these cancers [3].
Cancer care of solid tumors involves the detection, diagnosis, characterization, treatment,
and monitoring of the disease. Detection begins when, upon an initial indication, a radiology
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exam is requested for a patient. A radiologist then prompts an exam by determining
the content of the order based on the clinical context for the initial request including
the appropriate imaging modality (Computed Tomography or CT, Magnetic Resonance
Imaging or MRI, etc.), body part (breast, lung, brain, etc.), and image acquisition protocol
(with/without injection of contrast agent) [5]. Upon receiving the exam request, a radiology
session is scheduled and the images are acquired. A radiologist then reviews the images
and prepares a report containing the image findings. Image findings typically contain
detailed information regarding the key attributes of the lesion(s) including anatomic location,
qualitative and quantitative description of the lesion. The reported qualitative attributes of
the lesion(s) include the radiologist’s subjective visual description of the lesion such as lesion
shape, margin, and border or density.
Quantitative attributes of lesions are measures of tumor burden estimation and are rarely
reported in standard of care practice at initial detection [5] and are only presented during the
treatment planning phase as part of the treatment response assessment process. The content
of a radiology report at these stages includes the above-mentioned attributes, as well as an
estimation of comparison of lesion attributes (qualitative and quantitative) over time. The
criteria for measuring the lesion’s quantitative attributes are defined in Response Evaluation
criteria In Solid Tumors (RECIST), and/or Wold Health Organization (WHO). As shown in
Figure 1.1, estimation of tumor burden in clinical practice relies on human measurement of
one- or two-dimensional descriptors of tumor size [6, 7].
Following the initial diagnosis, the next step is characterization of the detected lesion.
The gold standard for characterizing lesions is the histopathologic analysis of tissue samples
acquired through surgical biopsy or resection [8]. Initial diagnosis (benign or malignant,
as well as grading) and genetic status of solid tumors are determined from tissue samples
obtained via a biopsy. Treatment of solid tumors may involve combination of tumor resection
through surgery, radiation therapy, and chemotherapy. Radiotherapy is a major part of the
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(a)
(b)
Figure 1.1: Measurement of tumor burden via RECIST and WHO response assessment
criteria. Measurements rely on (a) sum of longest diameters of target lesion in RECIST, and
(b) sum of products of the two longest axes in WHO criteria. In both criteria, measurements
are repeated over time, leading to an estimation of disease status into four categories:
complete response, partial response, stable disease, and progressive disease.
3
treatment process for roughly half of cancer patients and is particularly useful for cancers of
the head and neck, lung, bladder and prostate. Radiotherapy is also used as a pre-surgery
treatment to shrink the size of tumor in an attempt to control the spread of the disease
(i.e. in breast cancer) [9]. Radiotherapy is the only treatment option for locally advanced
cancers where the location of the lesion renders surgery an unsuitable option (i.e. cancer of
the larynx) [9]. The prescribed radiation dose depends on the type of cancer, the tolerance
of the surrounding normal tissue, and the amount of radiotherapy toxicity up to five years
past treatment [9].
Treatment of cancer via chemotherapy heavily depends on the information provided via
the acquired tissue samples. For decades, chemotherapy treatments of malignant lesions have
involved targeting rapidly dividing cancer cells using intravenous cytotoxic chemotherapy.
Due to the blind nature of this type of treatment many rapidly dividing normal cells (e.g.,
hair, gastrointestinal epithelium, bone marrow) are also affected leading to classic toxicities
for the patients (i.e. alopecia, gastrointestinal symptoms, and myelosuppression) [10]. Cancer
treatment has experienced a dramatic change as a result of the new advances towards
targeted therapies. In the age of targeted therapies particular monoclonal antibodies and
small molecule inhibitors are targeted to disrupt distinct mechanisms of tumor cells. Elements
such as the lesion cellular environment, including presence/absence of certain enzymes and
protein expression, cell type, presence/absence of gene alterations, level of oxygenation within
the cell, and growth factors all affect the course of treatment [11].
1.1 Motivation
Invasive biopsy or surgery procedures are the sole means for the provision of bio-specimen
samples that provide insight into tumor composition and molecular context. These invasive
procedures cannot be performed with an aggressive frequency; in fact, oncologists normally
rely on the information provided via two or three biopsies for their decisions during the
whole course of treatment.
4
An important factor to consider is that intra-tumor heterogeneity can vary among
cancer types and subtypes [12]. Because biopsy samples are extracted from a single (or two)
location(s) within the lesion, they can be narrow in scope and therefore fail to reflect the
variability of molecular structure of tumors [13]. In fact, they can only serve as a snapshot
of the tumor’s molecular structure at the time and location of biopsy sampling. This sets
a limitation on the utility of biopsy samples given that the heterogeneity of solid tumors
has been established at the phenotypic, physiologic, and genomics levels [14–16]. Another
drawback of biopsies is the narrow temporal scope of the information that they can provide.
Given that cancer is a phenotypically and molecularly progressive disease, the molecular
context of the disease changes over time. Hence, a single biopsy at a single time point may
not be able to convey the changes in the molecular context of the lesion [17].
Biopsy procedures are also susceptible to sampling error. Closed biopsies (with a needle,
endoscopy, the preferred biopsy procedure in complicated cases) have been shown to have a
lower rate of accuracy compared to open biopsies (with an incision), especially for soft-tissue
tumors [18]. The histopathology reports may contain errors as well. Nguyen et al. [19]
found an error rate of 44% in prostate pathology reports. The authors found that in 10% of
the pathology reports the errors were significant enough to change the course of treatment.
Another study [20] found that 7.8% of the breast cancer pathology reports included errors
significant enough to affect the choice between a lumpectomy and mastectomy for the
patients.
The high prevalence of cancer has prompted significant promotion in biomarker (defined
in Table 1.1) research, even though the utility of biomarkers in clinical domain doesn’t
start or end with cancer. This promotion is due to the fact that further advancement of
targeted therapies goes hand in hand with advancements of biomarker research. Biomarkers
are introduced at various stages of cancer to help identify cancer type and stage, forecast
the effect of treatment, monitor progress of the disease, and predict outcome (e.g. time to
relapse, survival) [21]. Thus, biomarkers offer many benefits for cancer care including faster,
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cheaper, more efficient diagnosis and treatment processes [8, 22], as well as smaller sample
sizes for clinical trials [21].
Table 1.1: Biomarker terminology (courtesy of [23])
Term Definition
Biological
Marker
(Biomarker)
A characteristic that is objectively measured and evaluated as an indica-
tor of normal biologic processes, pathogenic processes, or pharmacological
responses to a therapeutic intervention.
Clinical
endpoint
A characteristic or variable that reflects how a patient feels or functions, or
how long a patient survives.
Surrogate
endpoint
A biomarker intended to substitute for a clinical endpoint. A clinical inves-
tigator uses epidemiologic, therapeutic, pathophysiologic or other scientific
evidence to select a surrogate endpoint that is expected to predict clinical
benefit, harm or lack of benefit.
Useful
Biomarker
(1) Informs risk/benefit ratio when decisions are to be made.
(2) Does so in a better/safer/faster/earlier/cheaper way than existing ap-
proaches.
(3) Generally applicable: sample and technology must be available/accessible.
(4) Has a known identity.
An ideal cancer biomarker should follow the changes of the molecular context in which
they find themselves. Most new potential treatments fail to obtain regulatory approval
partly due to clinical trial biomarkers that are poor predictors of treatment effectiveness.
Within the context of solid tumors, bio-specimen samples such as biopsies serve as the
main source of biomarkers used in the treatment and monitoring of cancer. However, bio-
specimen biomarkers inherit the limitations of their source: biopsy samples. They offer limited
longitudinal granularity : A quality that is critical for assessing the impact of therapeutic
interventions on the molecular context of the disease [24]. To address this shortcoming
imaging biomarkers have been investigated. An imaging biomarker refers to “an imaged
characteristic that is objectively measured and evaluated as an indicator of normal biological
processes, pathogenic processes or a response to a therapeutic intervention” [25]. Lesion
size remains the only recognized imaging biomarker extracted from routine care imaging
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to evaluate the response to treatment. This is despite that lesion size doesn’t reflect the
complexity of lesion context and changes in its behavior [26]. Changes in tumor dynamics
are known to start much earlier than the any change in lesion size [26], meaning current
measurement criteria rely on a rather distal indicator of treatment effectiveness. Another
limitation of using lesion size as the primary imaging biomarker is that lesion size does not
predict patient prognosis such as overall or progression-free survival [5, 27]. Inter-reader and
intra-reader size measurement variability [28] along with inconsistency between readers in
selection of target and non-target lesions are among other limitations of this process [5]. These
issues are so widely known that the pharmaceutical companies often employ “independent
review panels” to standardize tumor response measurements in clinical trials [7]. Based on a
report by Thiesse and colleagues [29] on a large multicenter trial in oncology, the independent
review panels and the case radiologists were found to have major disagreement in 40% of the
cases and minor disagreements in a further 10.5% of cases. Qualitative descriptions are also
reported in radiology reports of cancers. To name a few, characteristics such as lesion margin,
shape, border, and intensity patterns (enhancement pattern, vascularity in breast lesions)
are among parameters that are reported qualitatively and therefore suffer from subjectivity
and measurement variability across readers.
1.2 Objective & Aims
The rise of high-throughput tools capable of massive processing of genomics data has
led to exciting advances in the field of computational biology. The ability to translocate
gene expression profiles of various tissues has provided us with an unprecedented snapshot
of disease signatures on a molecular and cellular level [30]. These advances are slowly
influencing how we view other data sources in health care. Imaging has traditionally been
viewed as a largely qualitative diagnostic tool; a means to provide important anatomical and
morphological information about the clinical question at hand. The vast amount of available
high quality imaging data is an excellent candidate for the analytical high-throughput
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approach. Recently, an emerging practice known as “radiomics” has been introduced to
investigate this opportunity. Radiomics refers to extraction and analysis of large numbers
of quantitative features from diagnostic images to improve disease characterization and
prediction of outcome [13, 26, 30, 31]. The findings of recent radiomics studies suggest the
potential for imaging data in quantification of tumor phenotypic characteristics to improve
biomarker research.
Radiomics research falls directly in the field of biomedical imaging informatics by pursuing
the effective use of imaging data, information, and knowledge for scientific inquiry, problem
solving and decision making. It also investigates how to reason on these data in order to effect
beneficial change in the healthcare enterprise. This thesis, therefore, focuses on contributing
to the body of research in the field of radiomics. The ultimate goal of this thesis is to improve
integration of imaging data in clinical decision making processes to improve patient outcome.
The intermediate goal is providing evidence of the utility of imaging data in the context of
other sources of knowledge such as clinical data to promote imaging biomarker discovery.
The research, therefore, unfolds over the following two aims.
AIM I Making imaging-derived information accessible:
The usefulness of images in developing decision support systems in dependent on
the availability of quantitative imaging data. To this end, an analytical informatics
pipeline is implemented for characterization of multiscale imaging data. This tool
is a comprehensive methodological pipeline for conversion of diagnostic images to
quantitative and mineable data. When pointed to an anatomical region with clinical
relevance, it extracts large numbers of quantitative features to objectively describe
the spatial and spectral appearance of the region on a pixel-by-pixel level. Images
from several modalities (Computed Tomography (CT), Magnetic Resonance Imaging
(MRI), Contrast Enhanced Spectral Mammography (CESM)) can be processed with
the pipeline.
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AIM II Bridging the gap of imaging-derived information and other biomedical
data:
The integration of quantitative features from biomedical images with other clinical
and genomic data is an ongoing area of research. Image-drived data can be used for
integration and construction of models that yield new insight about diseases, or can be
used for development of decision support tools to improve clinical practice. For this
aim, I focused on linking the imaging features with the context of diseases in which
imaging biomarkers have an established presence: cancer and Alzheimer’s disease. Four
retrospective validation studies were conducted to assess the utility of imaging data in
diagnostic applications, and if possible and relevant, to assess if using this data can
lead to improved diagnostic accuracy compared with that of clinical practice.
1.3 Overview of Chapters
Chapter 2 describes the background of the radiomics approach, focusing on the motivations
of radiomics, the literature in this field, and summary of a generic radiomics workflow. Chapter
3 presents technical details of the theoretical and methodological pipeline proposed in AIM I.
This chapter provides a description of preprocessing steps including image normalization
and segmentation of regions of interest. Analysis methods used for extraction of quantitative
features are described next followed by the summary of the analysis processes used for
assessing clinical utility of imaging-derived features.
Chapter 4 to 7 presents the validation studies conducted for fulfillment of AIM II. In
respective order, these chapters review studies related to sinonasal cancer (chapter 4), breast
cancer (chapter 5), human papillomavirus (chapter 6) and finally, the Alzheimer’s disease
(chapter 7). These chapters begin by a summary section in which the goal of the study,
details of the publication, and my contributions to the study are highlighted. Each chapter
follows the format required for publication: abstract, introduction, material and method,
results, discussion and conclusion.
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Some of the challenge in imaging biomarker discovery is resolving the technical and
standardization barriers to providing actionable evidence of imaging data. Chapter 8
highlights the challenges related to feature extraction, selection, and analysis processes and
their respective impact on the result. This chapter also discusses the future of radiomics
research and its impact in advancement of image-based diagnosis and biomedical imaging
informatics. The limitations of the pipeline presented in this thesis are discussed next.
Chapter 9 presents the conclusion of this research.
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Chapter 2
BACKGROUND LITERATURE
2.1 Introduction
In this chapter, I describe a recent paradigm for quantitative image analysis known as
radiomics. My aim for this chapter is to clarify what radiomics is and where it stands in the
spectrum of cancer research. First, the motivations and potential impacts of radiomics is
discussed particularly in relation to advancement of solid tumor cancer research. This section
is followed by a review of the findings of the latest literature. Next, high-level workflow of
radiomics is described including the input imaging data, feature extraction methods, and
challenges of data analysis.
2.2 Radiomics
Quantitative image analysis has a well-established footprint in cancer research. Imaging
traits have been used for characterization of healthy and pathologic tissues, for differentiation
of tumor regions, as well as for tumor grading. Some examples in this regard are the imaging
studies in brain [32–35], breast [36–41], lung [42, 43], and prostate [44] cancers. Imaging
qualities have also been used to predict prognosis markers such as time to progression and
survival rate of brain tumors [45], non-small cell lung cancer [46], colorectal cancer [47–49],
and renal cell cancer [50].
There are similarities between the radiomics approach and conventional quantitative
image analysis. They both explore imaging data for potential utility in treatment, monitoring,
outcome prediction, or biomarker discovery. However, radiomics differs from quantitative
image analysis in the high throughput approach to quantification of tumor phenotypes. By
facilitating extraction of large quantities of information from diagnostic imaging radiomics
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not only leads to comprehensive assessment of the clinical utility of the imaging features,
but also serves as a bench mark to standardize feature extraction and analysis processes.
Radiomics data has shown potential in reflecting the complexity of tumor composition
and behavior. By promptly detecting small and early focal responses this data can lead
to enhanced tumor characterization and response assessment. Advocates of radiomics are
motivated by the fact that imaging is nearly non-invasive (completely when no contrast agent
is injected) and can shed light on the lesion state in its entirety even in complicated cases
where biopsy procedures are risky. Moreover, the extracted imaging information may prove to
be complementary or interchangeable with other sources, i.e. demographics, pathology, blood
biomarkers, genomics [13]. Hence, radiomics can lead to earlier termination of ineffective
treatment plans leading to lower cost of treatment and enhanced quality of life during
treatment for the patient.
Growth of radiomics research can potentially lead to the progress of imaging biomarker
research. Alizadeh and colleagues [51] identify blood-borne biomarkers as the main non-
invasive physical source for gaining insight into the molecular composition of tumors. Cell-free
DNA and circulating tumor cells can be accessed through blood samples to provide insight
into the molecular composition of tumors. However, blood samples have a fundamental
limitation, as they discuss: “It is unclear whether primary tumors or metastases contribute
more to the pool of circulating cancer material. It seems clear, however, that even if
circulating material is found to faithfully reflect the tumor itself, there is still a need for more
efficient ways of isolating the cells and nucleic acids from the blood and for data analysis tools
that can more faithfully reconstruct the parent tumor”. Upon validation, radiomics imaging
traits can breed non-invasive biomarkers that can be identified as surrogates for important
clinical outcomes [52]. These biomarkers can be utilized in various stages of cancer care such
as detection, diagnosis, assessment of prognosis, prediction of response to treatment, and
monitoring [31].
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2.2.1 Radiogenomics
One of the emerging areas in this area of study is known as Radiogenomics. This term
has been used in the literature to describe two quite different concepts: (1) the practice of
analyzing whole genome to enhance our understanding of molecular pathogenesis and risk
factors of variation in radiotherapy toxicity [9, 53, 54], (2) establishing association maps
between radiomics data and genomics (or other -omics) data. To clarify, here we refer to the
latter definition which has also been described as ’Imagenomics’ in the literature [55].
Radiogenomics focuses on mapping the quantitative imaging input to the findings of
computational biology. A major motivation behind radiogenomics studies is that imaging
is already part of routine diagnostics, an advantage that gene expression profiling is only
beginning to develop [13, 30]. In contrast to genomics profiling, virtually all patients go
through imaging multiple times during their treatment [31] and, given the non-invasive nature
of the procedure, imaging can theoretically be repeated as often as required. Therefore, by
establishing association maps between imaging traits and previously determined treatment
response or gene-expression findings, radiogenomics can lead to non-invasive imaging sig-
natures for the genomics pathways and a shift towards individualized medicine in routine
care.
Given that genomics profiling is not available for all the patients who go through cancer
treatment, radiogenomics can potentially offer two services for advancing targeted therapies
towards a more genetically informed paradigm. Firstly, radiogenomics offers the possibility of
mapping the distribution of genomics markers across the entirety of lesion. Genomics markers
are detected from local and temporal tissue samples. By building association maps between
these markers and imaging traits, radiogenomics can introduce radiophenotypes, specific
image phenotypes that associate with presence/absence of genes [52]. These characteristics
can serve as surrogates for gene expression signatures [30]. If such association maps are
established and validated, radiogenomics can detect where in other parts of the lesion those
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imaging traits are present and therefore prompt biopsy procedures to target more specific
areas of tumors [56]. Secondly, radiogenomics can serve as an independent source of additional
information to inform on how a biological process is reflected in images [52]. Such information
could be merged with genomics data leading to enhanced diagnostic and prognostic power
[31].
2.3 Examples of Radiomics Literature
Aerts and colleagues [27] showed that it is possible to identify imaging traits that are
consistent across multiple datasets and associate them with tumor prognosis. They conducted
a study in which 440 features were extracted to quantify tumor intensity, shape and texture
on the CT images of patients with lung or head-and-neck cancer. Features were found to
have significant association with tumor histology, and to have prognostic power in seven
independent datasets. The authors also found associations between radiomics features and the
gene-expression profiles of lung cancer patients in one dataset. Along these lines, Parmar and
colleagues [57] investigated cancer-specific radiomic feature clusters in four independent Lung
and head-and-neck cancer cohorts. Several feature clusters, extracted from the pre-treatment
CT images, exhibited stability across the datasets. The authors found strong associations of
these features with lung prognosis and staging of head and neck lesions.
Coroller and colleagues [58] extracted 635 radiomic features from pre-treatment CT-scans
of lung adenocarcinoma patients. 35 features were predictive of distant metastasis (DM),
and 12 features showed correlation with survival. The authors concluded that, given the
strong power of their radiomics signature in predicting DM, the result could be used as a
prognostic biomarker for factors such as distant metastasis.
Hu and colleagues [17] highlighted how radiomics can serve as a noninvasive means to
potentially predict histopathology. They extracted 900+ texture features from various MRI
contrasts of Glioblastoma Multiforme (GBM) lesions at the biopsy locations. The authors
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Figure 2.1: Prediction of tumor content in Glioblastoma Multiforme (GBM) using radiomics
data (courtesy of Hu et al. [17]). Authors generated a model to bridge the gap betweem
radiomics features extracted from MRI images and tumor content of biopsy samples. This
figure shows the success of their model on two previously unseen cases in the validation
set. (A, B, C, E) Biopsy locations within the non-enhancing (green dots, arrows) on T1+C
(A, D) and T2W (B, E) images corresponding with high-tumor (>80% tumor nuclei) and
low-tumor (<80% tumor nuclei) tissue samples on histologic analysis. Colormaps (C, F) with
manual tracings (green) show the probability (range 0-1) of tumor-rich (red) vs tumor-poor
(green/blue) content across the tumor for the two cases.
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generated a classification model that predicted the percentage of tumor content from the
texture features. Figure 2.1 shows the colormap overlay of their predictions across the entire
lesions in two validation cases. Hu and colleagues [56] also predicted local gene expression
data through multivariate analysis of copy number variant (CNV) status, multi-parametric
MRI, and texture analysis. This study proposed that a radiomics model with an acceptable
level of success in the prediction of the presence of a certain gene can provide invaluable
information to guide further biopsy procedures. Figure 2.2 shows the proposed tree model of
imaging features for prediction of PDGFRA amplification (Part A), along with colormap
overlay of prediction (Part C) on 2 stereotactic biopsies (Part B) for a validation case.
Figure 2.2: Radiogenomics model for GBM (Figure courtesy of [56]). (A) (P= isotropic
diffusion; EPI+C=T2*W signal loss; DOST=discrete orthonormal Stockwell transform; PC3,
PC2 derived from principal component analysis (PCA), AUC, area under curve). (B) the
locations of 2 stereotactic biopsies (Bx#1, Bx#2) on CE-MRI. DNA CNVs demonstrated
amplification (Amp, Bx#1) and diploid/wild-type status (WT, Bx#2). (C) regions (ROIs)
of predicted PDGFRA amplification (red voxels) using tree model classification.
16
Zinn and others [59] identified and corroborated genomic correlates of edema/cellular
invasion in GBM with MRI phenotypes. Gevaert and others [60] extracted quantitative
image features from the enhancing necrotic part of GBM tumor and peritumoral edema on
MR images. Their radiogenomics map linked 56% of the 50+ imaging features with biologic
processes, while 3 and 7 imaging features were significantly correlated with survival and
molecular subgroups, respectively. Focusing on GBMs, Diehn et al. [61] showed initial proof
that a radiogenomics approach could potentially be used in selecting patients for targeted
therapies. They identified an imaging biomarker of EGFR expression from MR images; an
image trait termed “contrast necrosis” highly associated with EGFR gene expression. They
effectively utilized this image trait to select GBM patients with over-expressed EGFR protein.
In a clear cell renal cell carcinoma application, Karlo and others [62] found associations
between known genetic mutations and imaging traits describing the tumor margin, size,
vascularity, and enhancement on pretreatment CT images. Segal and colleagues [63] associated
distinctive imaging traits in CT scans with global gene expression profiles of liver cancer
related to angiogenesis (such as vascular endothelial growth factor, VEGF). Their results
showed association maps between 28 features and 78% of the global gene expression profiles.
In a preliminary breast cancer radiogenomics study, Yamamoto and colleagues [64] provided
an association map linking MR image phenotypes to underlying global gene expression
patterns. They found 21 (out of 26) imaging traits of breast MRI as globally correlated with
71% of the total genes measured in patients with breast cancer.
2.4 Workflow of Radiomics
Implementation of the radiomics approach (in the traditional learning scheme) involves the
following discrete processes: (a) image acquisition, (b) segmentation, (c) feature extraction,
(d) feature analysis and model generation. In this section, we briefly describe each of these
steps. Figure 2.3 shows the simplified workflow of the training and application of the radiomics
approach. Step 1 shows the training phase of the workflow in a conventional learning scheme
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which is bound by preparation of feature sets. In this learning scheme, a high number of
features are extracted from diagnostic images via a radiomics engine (part a). These features
are then analyzed in the prediction engine (part b) using machine learning techniques. The
output of the prediction engine divides the high dimensional feature space of radiomics to
a much simpler classification space (part c) to assess the clinical hypothesis of the dataset.
Step 2 shows how this pipeline can be applied for prediction of the result in a previously
unseen case.
Figure 2.3: A simplified radiomics workflow. In training phase (Step 1) a high number of
features are extracted from diagnostic images via a radiomics engine and are used to generate
a low dimensional classification space from the training data. The classification model is
used on unknown cases in Step 2.
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2.5 Inputs of the Radiomics Engine
Just as cancer therapy research has advanced, so too has cancer imaging, resulting in
images with higher temporal resolution (number of frames per unit time), spatial resolution
(number of image pixels per spatial unit), and contrast resolution (number of bits per pixel).
Depending upon the cancerous organ, the location of metastasis, and patient tolerance to
the procedure, various imaging modalities are ordered. Some well-known image modalities
are Computed Tomography (CT), Magnetic Resonance Image (MRI), or Positron Emission
Tomography (PET).
CT scans can provide high resolution structural information about the location and shape
of lesions [65]. When combined with contrast injection, CT scans exhibit strong contrast
reflecting the presence of underlying disease or injury in the organs, blood vessels and/or
tissue types [27]. CT perfusion shows which areas are perfused adequately with blood and
provides detailed functional information on delivery of blood or blood flow to specific organs.
Figure 2.4: MRI images of brain with tumor viewed in axial plane. The arrows show the
location of glioblastoma multiforme (GBM) on (a) standard pre-contrast T1-weighted, (b)
post-contrast T1-weighted, and (c) pre-contrast T2-weighted sequences.
Tumor functional and molecular characteristics are assessed using Magnetic Resonance
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Imaging (MRI). The use of different spin-echo sequences for capturing MRI results in
exhibition of different functionalities of lesions. MRI contrast may be weighted to demonstrate
different anatomical structures or pathologies (Figure 2.4). For instance, T1-weighed MRI is
used for obtaining morphological information while MR diffusion weighted, Flair sequences
and T2-weighted are useful as measures of cellularity, edema and inflammation. MR diffusion
has been reported to detect early changes that correlate with tumor response [66, 67].
Lesion perfusion is captured using dynamic contrast enhanced-magnetic resonance imaging
or DCE-MRI, providing information on lesion blood flow, permeability, and angiogenesis [68].
Diffusion-weighted MRI (DW-MRI) holds promise for use as a cancer treatment response
biomarker as it is sensitive to macromolecular and micro structural changes which can occur
at the cellular level earlier than anatomical changes during therapy [69].
Tumor metabolism is assessed using a type of nuclear medicine imaging known as
Positron Emission Tomography (PET) imaging. PET imaging provides important information
regarding blood flow, oxygen use, and sugar metabolism of lesions. However, PET has limited
spatial resolution. More recent developments in imaging have resulted in devices that perform
imaging via dual sources such as PET/CT and PET/MR [70, 71]. However, the standard-of-
care imaging modalities such as CT and MRI are the most explored imaging modalities for
incorporation in radiomics workflows due to the potential impact in routine care [72–74].
Regardless of imaging modality, the next step prior to the extraction of radiomics features
is segmentation of the region(s) of interest. Lesion segmentation is performed to precisely
define the spatial extent of the lesion on the images. The validity of the segmentation result is
of utmost importance because of its direct impact on the radiomics features and the utility of
their content. Prior to segmentation, several image preprocessing steps are requisite, including
spatial registration of different image sequences and modalities, noise reduction, and intensity
calibration to account for the differences in the anatomical and intensity variations of the
images.
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Manual outlining by an expert is considered the ground truth in tumor segmentation.
However, the result of manual segmentation can be unreliable due to inter and intra reader
segmentation variability [75]. Moreover, outlining a 3D volumetric object manually is a
tedious and time consuming task rendering it impractical. In comparison, semi-automatic
methods involve a minimal amount of input from an expert user (e.g., a seed point to
initialize the segmentation or manual editing of the results). Region growing methods, level
set methods, graph cut methods, active contour algorithms and semi-automatic segmentations
such as livewires are among the most widely used segmentation approaches [26]. Automatic
and semi-automatic segmentation methods are the preferred method of segmentation in
radiomics worflows due to their robustness and significantly higher levels of reproducibility
[76].
2.6 Feature Extraction
Radiomics features cover a wide range of quantitative attributes including shape, margin,
boundary, intensity, texture, etc. Lesion shape, boundary, margin, and location are established
prognostic measures, and are already a part of the radiologists’ lexicons for description of
lesions [31]. In regard to this group of features, the goal of the radiomics approach is to
introduce quantitative measurements to reduce variations of image interpretation due to
human error and inter-observer variability [39, 77].
Biomedical texture information relates to the micro- and macro- structural properties
of biomedical tissue. Texture descriptors are generally divided into three major categories:
statistical, structural, and spectral. Statistical texture features are non-deterministic descrip-
tors of the distribution of gray-level intensities in a region of interest. First order statistical
features (i.e. mean, max, min, variance, kurtosis) are histogram-based descriptors of intensity
distribution and can only provide global information regarding the target region intensity
pattern. Second order statistical features describe inter-relationships of gray-level values
within a region and are the most widely used feature extraction method in medical pattern
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recognition tasks. gray level co-occurrence matrices (GLCM) [78] and gray level run length
matrices (GLRLM)[79] are two instances of this group. In GLCM, a variety of features are
used to describe a matrix generated from the observed frequency of gray-level combinations
within neighboring pixels, while in GLRLM the focus is on describing coarseness of texture
in predefined directions. The utility and efficacy of GLRLM in comparison with GLCM or
spectral methods were debated in the early stages [80, 81], however it has been increasingly
investigated for clinical applications in the last decade [82–84]. Grey-scale and rotationally
invariant Local Binary Patterns (LBP) [85] is another statistical descriptor of texture focusing
on the patterns of intensity transition within the sub regions of an area of interest. The
radius of the sub regions determines the scale of the texture described by the LBP features.
Structural descriptors view texture in terms of texture primitives such as micro and macro
textures. Model-based features describe the region of interest through mathematical models
such as fractals or stochastic models [86]. There are fewer reported radiomics applications for
structural and model-based methods (an example: [87]), as they are viewed as more suitable
for synthesis than analysis.
Spectral descriptors rely on the frequency or scale domain representation of the region
of interest for calculation of texture features. By adjusting the window/filter expansion in
space or frequency, these transform-based methods allow for multi-resolution, multi-scale
representation of texture. The wavelet transform (WT) [88], the Riesz transform [89], the
Stockwell transform (ST) [90], the Discrete Orthonormal Stockwell Transform (DOST) [91]
and the Polar Stockwell Transform (PST) [92], Gabor filter banks (GFB) [93], and Laplacian
of Gaussian Histograms (LoGHist) [94] are only some examples of this group.
2.7 Predictive Engine
The predictive engine is in charge of extracting clinically relevant information from the
large amount of data generated using the radiomics approach. Dimensionality reduction and
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feature selection are two of the fundamental building blocks of this engine and are responsible
for selecting and/or generating valuable features from the large number of often-redundant
radiomics features. Selected features can be used to build predictive models of clinical
endpoints such as patient survival and tumor progress or models that predict diagnostic
information such as tumor stage and tumor diagnosis. Predictive modeling generally involves
a type of supervised learning scheme in which the labels of samples (i.e. tumor stage,
diagnosis, or pathology) are presented to the classifier for a subset of the available data
known as training set. The model is later tested by predicting the label of previously unseen
data (2.3).
A certain classification approach might be better suited for a type of data based on the
characteristics of the data and the manner in which the classification approach is utilized [95].
Designing the best classification approach that can lead to stable and reproducible models
requires a substantial amount of knowledge in machine-learning and statistical inference.
The interested reader is referred to [96–98] for more information.
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Chapter 3
METHODOLOGICAL PIPELINE: A RADIOMICS APPROACH TO IMAGE ANALYSIS
3.1 Summary
This chapter describes the methodological pipeline that has been proposed in fulfillment
of specific AIM I. Beginning with the overall description of the platform, this chapter provides
the steps involved in preprocessing of biomedical images and extraction of region of interest.
Next, feature descriptors are explained in detail including intensity-based, statistical, and
spectral texture features. To finalize, machine learning techniques and statistical analysis
used along with this pipeline are presented.
3.2 Proposed Platform
The pipeline presented here follows the genreric radiomics workflow described in chapter
2. This pipeline provides a path for quantitative analysis of image texture and intensity along
with a selected number of morphological features (shape descriptors). Although a universally
agreed-upon definition of texture does not exist among the experts, it is often described as the
patterns perceived by humans that reflect the spatial organization or repeated sub-patterns
of the image. Several feature extraction algorithms are included in this pipeline that examine
brightness distributions or spectral representation within the region, searching for spatial
relations between pixels that have particular gray levels. The pipeline computes numerical
values that correspond to intrinsic properties of texture and intensity.
Texture can not be detected in a single pixel (or voxel). These patterns can only be
characterized within sufficiently large regions that can contain several repeated patterns or
a texture fragment which is representative for a whole texture. Similarly, the whole image
cannot be the input for texture feature computation because the features won’t correctly
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reflect characteristics of particular objects or meaningful areas. A region of interest therefore
is required to limit the area from which the features are computed. These regions are
provided to the pipeline as input files.
There are two modes for feature computation in this package. The first mode computes
features from a user defined region of interest to provide a numeric representation of the
region as a whole. In this mode, the pipeline provides a close-to-optimal description of the
region by computing features that describe incremental degrees of texture scales. The second
mode computes features from a sliding small window placed around every image pixel within
a large region of interest, capturing the variability of small scale texture features across a
large region.
The inputs of the pipeline are 2D images or slices and a file that provides the coordinates
of the region of interest boundary (with ’.txt’ or ’.roi’ extensions). Features extraction
algorithms included in the pipeline are listed in Table 3.1. The output of the pipeline is
a spreadsheet in which columns are image modality, patient Identification number, slice
number, size of the region of interest, and the name of the numeric features. The rows
represent the values of columns for each patient. The script for this pipeline is written in the
platform-independent and open source Python[99] programming language.
3.2.1 Preprocessing
Figure 3.1 shows the steps involved in preprocessing of images. Inputs to the pipeline are
the address of a root folder where images and the region of interest (ROI) files physically exist,
as well as the format of images (DICOM, or generic image formats such as PNG/JPEG/TIFF)
and the format of ROI files. To ensure similarity of images, several image properties are
assessed and matched across the cohort including image dimensions (image size), image pixel
spacings (physical size of a pixel in x and y directions), and dynamic range of images (range
of intensity levels). Image resampling is performed when inconsistencies are observed in pixel
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spacings and image dimensions of images. These preprocessing steps are necessary to ensure
that the difference among subsequent texture features are not the result of imaging protocol
or image acquisition settings.
Table 3.1: Texture Descriptors Included in the Platform
default # features for a region
Algo. Description Category size: 8x8 size:16x16 size:32x32
- Raw Intensity Statistical 3 3 3
Descriptors
Gray Level
GLCM Co-occurence Statistical 26 26 26
Matrices
LBP Local Binary Statistical 12 12 12
Patterns
GFB Gabor Filter Spectral 8 8 8
Banks
DOST Discrete Orthonormal Spectral 6 10 15
Stockwell Transform
LoGH Laplacian of Spectral 18 18 18
Gaussian Histograms
Segmentation of the ROIs is the next preprocessing step, in which the pipeline loads the
ROI files and select the regions of interest from the images. The ROI files provide image
coordinates of the boundary of a selected region with a clinical relevance. The ROIs are
the result of manual outlining by an expert and can include either coordinates of a selected
rectangular area or coordinates of a closed free-form boundary. Given that a larger area
can result in a larger number of features, at this step the pipeline compares the sizes of
the regions of interest and calculates the size of the largest square-shaped region that can
be extracted from all cases, while remaining within the boundaries of the ROI file. This
leads to extraction of sub-images which are input of feature extraction engine. One last step
before feature extraction is intensity normalization of sub-images to a common dynamic
range to ensure that the subsequent features characterize the sub-image texture exclusively
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and do not depend on any global imaging characteristics such as the overall brightness or
illumination of images.
Figure 3.1: Image Preprocessing Steps. Provided with a the address of a root folder, images
and ROI files are processed to select a common size of region of interest for analysis.
3.2.2 Feature Extraction
The Feature extraction module is the heart of the pipeline that generates two categories
of features: texture descriptors, and shape descriptors. Texture descriptors can be further
divided into three categories: Intensity-based, statistics-based, and transform-based measures.
Intensity-based features are first-order statistics of the histogram of pixel intensities
(Figure 3.2). Features computed in this method are simply statistical descriptors of the
histogram distribution (pdf) such as: mean brightness, variance, skewness, kurtosis and
percentiles. Because these features disregard the spatial relations between the pixels within
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Figure 3.2: Intensity-based features are first-order statistics of the histogram of pixel
intensities. Examples are mean brightness, variance, skewness, kurtosis and percentiles.
the image some disagreement exists in the literature about whether or not they should be
considered texture features. Nonetheless, they are descriptors of the visual appearance of the
image as a whole and are generally reported along with established texture features. This
pipeline includes mean, range, and standard deviation of the gray-level intensities from this
category. These features are computed before the final preprocessing step (dynamic range
normalization) to report the visual appearance of the original image.
The Next group is statistical texture descriptors which attempt to provide insight into
local intensity distributions within the region. The module includes two statistical texture
descriptors: Gray Level Cooccurrence Matrices (GLCM) and Local Binary Patterns (LBP).
The gray-level co-occurrence matrix (GLCM) [78] is a second-order histogram, computed from
the intensities of pairs of pixels. The popularity of GLCM lies in its simplicity. Each element
in the co-occurrence matrix shows how often a pair of intensity levels is seen in a neighborhood
defined with a certain angle and distance (Figure 3.3). A GLCM matrix is computed per
one direction/angle at a time. In order to produce unidirectional and rotationally-invariant
features, several matrices are computed and merged by either regrouping the counts of
operators over all directions in a shared matrix, or by averaging scalar texture measurements
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Figure 3.3: GLCM matrices are calculated per a distance and an angle. The matrix in right
is calculated for the image in the left for distance of 1 and the horizontal direction. The
element (1, 1) in the matrix contains the value of 2 because there are two instance in the
input image where two horizontally adjacent pixels have the values 1 and 1. The element
(5, 2) in the matrix contains the value of 1 because there is only one instance where two
horizontally adjacent pixels have the values 5 and 2. This process is continued, scanning the
image for other pixel pairs (i, j) for remaining directions (and potentially radii).
from the matrices obtained with different directions. In this pipeline 4 directions are
accounted for 0◦, 45◦, 90◦, and 135◦ to produce isotropic texture features. The radius of 1
is used as default to describe spatial relationships between immediately neighboring pixels.
The radius can be adjusted to capture these relationships across larger neighboring regions.
A set of 13 features are calculated using this method, examples of which are presented in
Table 3.2. This pipeline computes the mean and range of the set of features for a total of 26
features.
Rotationally-invariant local binary patterns (LBP) [85] focus on intensity distributions
of neighboring areas inside the region. Given a radius, this method places a patch with that
radius around every pixel in the region. The choice of the neighborhood radius defines the
scale of features described by this method. In each round, the intensities of the pixels around
a patch are converted to binary values based on whether intensities are greater or lesser
than that of the center point (Figure 3.4). The binary levels for each patch are aggregated
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Table 3.2: Texture Features from GLCM. The reader is referred to [78] for the complete list
of features.
Feature Formula Description
Angular Also known as uniformity and homogeneity,
Second
N−1∑
i,j=0
(
Pij
)2 ASM is high when image is homogeneous.
Moment
Contrast
√√√√N−1∑
i,j=0
(
Pij
)2 Square root of ASM.
measure of randomness of matrices.
Entropy
N−1∑
i,j=0
−ln (Pij)Pij Inhomogeneous scenes have low first order
entropy.
Variance Variance or sum of squares. This feature puts
N−1∑
i,j=0
Pij (i− µ)2 relatively high weights on the elements that
differ from the average intensity value.
Correlation
N−1∑
i,j=0
(i− µi) (j − µj)Pij
σiσj
Measure of gray-tone linear dependencies.
Inverse IDM is the local homogeneity. It is high
Difference
N−1∑
i,j=0
Pij
1 + |i− j|2 when local gray level is uniform.
Moment
Pij = Element i,j of the normalized symmetrical GLCM
µi =
N−1∑
i=0
iPij , µj =
N−1∑
j=0
jPij , σ
2
i =
N−1∑
i,j=0
Pij (i− µ)2 , σ2j =
N−1∑
i,j=0
Pij (j − µ)2
and converted to a binary code which corresponds to a decimal value. Aggregated decimal
values for the whole region are organized into a histogram from which the LBP features are
extracted. These features can be either normalized counts of histogram bins or descriptors
of histogram shape such as mean, variance, skewness and kurtosis. Default setting calculates
local binary patterns for the radius of 3. Normalized bin counts of a 12-bin histogram are
reported as the set of LBP features.
Transform-based texture descriptors are computed using 3 methods: Discrete Orthonormal
Stockwell Transform (DOST), Gabor Filter Banks (GFB), and Laplacian of Gaussian
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Figure 3.4: The circularly symmetric neighbor set of eight pixels in a 3x3 neighborhood. A)
The gray-level intensity of the center pixel (g0) is compared with the gray values of the eight
surrounding pixels of the circularly symmetric neighborhood. The result is a binary code
that defines the transition of pixel intensities across the neighborhood. B) Two examples of
a 3x3 region along with the LBP binary codes and the final digits.
Histograms (LoGHist). The methods use convolution as the type of linear operation used to
apply the texture operator to the image. A convolution in the spatial domain corresponds to
a multiplication in the Fourier domain.
Discrete Orthonormal Stockwell Transform (DOST) [91] provides a multi-resolution
spatial-frequency representation of an image. The process of calculating DOST features for a
2D image begins with defining the forward 2D Fourier Transform (FT) of a discrete function
f (x, y) which is assumed to have sampling interval of one in the x- and y- directions:
H [m,n] =
M−1∑
x=0
N−1∑
y=0
h [x, y] e−2pii(
mx
M
+ny
N )
And the inverse 2D-FT:
h [x, y] = 1MN
M/2−1∑
m=−M/2
N/2−1∑
n=−N/2
H [m,n] e2pii(
mx
M
+ny
N )
Next a dyadic sampling scheme (orders 0, 1, 2, ..., Log N-1) is used to partition the 2D
FT space into non-overlapping sections. The 2D-DOST of a NxN image h[x, y] is therefore
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calculated by partitioning the 2D-FT of the image, H[m,n], multiplying by the square root
of the number of points in the partition and performing an inverse 2D-FT,
S [x′, y′, νx, νy] = 1√
2px+py−2
2px−2−1∑
m=−2px−2
2py−2−1∑
n=−2py−2
H [m+ νx, n+ νy] e
2pii
(
mx′
2px−1+
ny′
2py−1
)
where vx = 2px−1 + 2px−2 and vy = 2py−1 + 2py−2 are the horizontal and vertical “voice
frequencies”. The spectrum is partitioned such that the wave numbers (νx0, νy0) are shifted
to the zero wave number point, a 2px−1 x 2py−1 inverse FFT is performed, resulting in a
rectangular (in general) voice image of 2px−1 x 2py−1 points. In this package rotationally
invariant features are calculated from the DOST image by averaging the magnitude of the
horizontal and vertical frequency values for each order.
Gabor filter banks [93] is another spectral method included in this pipeline. This methods
captures frequency content of the ROI through filtering the ROI with 2D Gabor filters.
Gabor filters are described by their orientation (θ), central frequency (f) and bandwidths in
horizontal and vertical directions (σx, σy). The equation of Gabor filter in the frequency
domain is:
G(u, ν, f, θ) = 12piσuσν
[
exp(−12
(
(uθ−u0)2
σ2u
+ (νθ−ν0)
2
σ2ν
)
+ exp(−12
(
(uθ+u0)
2
σ2u
+ (νθ+ν0)
2
σ2ν
)
)
]

uθ = ucosθ + νsinθ νθ = −usinθ + νcosθ
u0 =
2picosθ
f ν0 =
2pisinθ
f
σu,ν =
1
2piσx,y
Gabor filters are handcrafted and reflect upon only a section of the frequency representa-
tion of the ROI. Therefore, their success in capturing the true frequency content of the ROI
depends on the choice of filter shape, frequency, and bandwidths. In our experience with
these filters, σx = σy = (1.0, 3.0) and f = (0.6, 1.0) showed successful for small ROIs of sizes
8x8 - 16x16. For larger ROIs, the pipeline computes features for a wide range of Gabor filter
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shapes and sizes (as reported in chapter 4). Mean and standard deviation of each filtered
image are reported as Gabor features.
Laplacian of Gaussian [94] or LoG is the last convolutional texture processing approach
included in the pipeline. LoG uses a radial second-order derivative of a 2-dimensional
Gaussian filter as:
gσi(x) = − 1piσ2i
(
1− ‖x‖2
2σ2i
)
e
− ‖x‖2
2σ2
i
where σi defines the scale of the Gaussian filter. All structures at scales much smaller than
a particular σ are blurred leaving only textural information of a particular scale. Isotropic
multi-scale texture measures can be obtained by reporting the absolute values or the energies
of the band-pass filtered maps. Default setting for computation of LoGhist features in this
pipeline is set for Gaussian filters of σ = (2.0, 4.0, 6.0) to cover a range of fine to medium scale
textures. The pipeline then calculates statistical features (i.e. kurtosis, skewness, standard
deviation, mean, entropy, and uniformity) for the normalized histogram of the LoGs. The
said features are reported for each level of σ, counting up to a total of 18 LogHist features.
Four shape features are also included in the package. These features are extracted from
cases where the region outline has clinical relevance, for instance breast cancer in which
irregular shape of the lesion is an indication of malignancy. There are currently 4 shape
irregularity descriptors, described in [100], included in the pipeline. These features quantify
the similarity of the lesion boundary to a circle.
3.2.3 Feature Analysis
The number of features computed by this pipeline is large, reaching 73 features for an 8x8
region. Consequently an analysis engine is required to provide meaningful information related
to the clinical utility of these features. However, the choice of the analysis approach depends
highly on the data at hand and the question of the study. Therefore the analysis engine of
33
this pipeline is not hard-coded. Nonetheless, a number of frequently-used techniques for
statistical analysis, dimensionality reduction, feature selection, and classification have been
scripted in the pipeline. These scripts borrow from python-based open source libraries such
as Scipy[101] and Scikit-Learn[102].
Hypothesis testing is implemented using 2-sided tests with statistical significance level
defined as P < 0.05. 2-sample t test are performed for univariate comparison of features
between different groups before the application of machine-learning methodology. P-values
are corrected for multiple comparisons using the false discovery rate [103].
Given that high number of features can cause classifier overfitting, dimensionality re-
duction is an important pre-classification step. In this step the original feature space is
transformed into a new space of lower dimensionality to increases the chance of capturing
underlying relationships presumably present in the data and increase predictive performance
of the models on unseen data. This pipeline includes dimensionality reduction technique
using Principle Component Analysis (PCA) [104]. PCs are linear combinations of features
and are uncorrelated and ordered accordingly to their standard deviations. PCA is performed
separately for each texture algorithm and imaging source. Imaging source in this context
refers to any factor that affect the content of the image, examples are image modality (CT,
MRI, or Mammography), Imaging sequence (T1, T2, or post-contrast T1 for MRI), and
image view (i.e. two common views of image acquisition in mammography imaging). The
PCs can contain a certain level of the variability within a feature set (i.e. 80% - 95%). These
PCs are used for further processing. PCs are computed on features of all patients regardless
of diagnosis.
A critical step in modeling and analysis is feature selection. Feature selection is performed
to avoid overfitting to noise and to remove redundant features. Given that in the radiomics
approach the focus is on being thorough, it often computes a large number of features, many
of which are either highly correlated with each other or are redundant. There are two
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general strategies to feature selection. Filter strategy estimates the value of each attribute
individually, resulting in low computational complexity. These methods can be applied
prior to classification, possibly in conjunction with a random sampling approach, to serve as
another dimensionality reduction technique. However, filter-based feature selection strategy
may not be able to reveal the actual discriminative power as it views each feature independent
of the others. An alternative is the wrapper approach in which utilizes a search method to
search through the whole feature space and identify a relevant and non-redundant feature
subset [105].
This pipeline includes Sequential Forward Feature Selection (SFFS)[104] method. SFFS
starts with an empty set of features estimating discriminative power of individual features.
Features are gradually added to the feature with highest power so that all combinations of
feature pairs are examined. This method offers minimal redundancy but maximal relevance of
features. SFFS can also or be wrapped in model generation and classification. The criterion
that we used for adding features in SFFS is accuracy of the feature set, meaning features
were added to the set as long as they contributed to the accuracy of leave one out cross
validation beyond 1% or 5%. Threshold of 5% was used when the available data sample size
didn’t allow for separate train and test sets to reduce the possibility of overfitting.
Several classification (individual and ensemble algorithms) approaches have also been
scripted in the pipeline and are available for use with minimal modification. Examples are
Support Vector Machines (SVM), random forests, and Diagonal Quadratic Discriminant
Analysis (DQDA). These methods were particularly selected since they are among supervised
classification methods that have elicited good performance for high dimensional data with
small sample sizes. Leave one out cross validation and splitting samples are implemented
to assess the model performance on trainset. ROC curves statistics such as sensitivity,
specificity, accuracy, area under the ROC curve, confidence intervals of the area under the
ROC curve, and model significane are reported as the metrics of model evaluation. The
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classification models is also stored for future validation studies where generalizability of the
models can be assessed by testing them against previously unseen data.
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Chapter 4
VALIDATION STUDY I: MRI-BASED TEXTURE ANALYSIS TO DISTINGUISH
SINONASAL SQUAMOUS CELL CARCINOMA FROM INVERTED PAPILLOMA
4.1 Summary
This chapter reports on a retrospective pilot study to bridge between imaging-derived
features and pathology results. In this study we evaluated the utility of imaging-derived
features extracted from MRI images in detecting signature appearance of sinonasal tumors
on MRI images. This work was published in American Journal of Neuroradiology in 2017
[1] and was presented at the Annual Meeting of the North American Skull Base Society,
February 12-14, 2016, Scottsdale, Arizona. My contributions to this manuscript are: 1)
devising technical design of the study, 2) implementing the the image analysis process, 3)
implementing the machine learning process, 4) writing and editing the manuscript.
4.2 Abstract
Background and Purpose: Because sinonasal inverted papilloma can harbor squamous
cell carcinoma, differentiating these tumors is relevant. The objectives of this study were
to determine whether MR imaging-based texture analysis can accurately classify cases
of noncoexistent squamous cell carcinoma and inverted papilloma and to compare this
classification performance with neuroradiologists’ review.
Materials and Methods: Adult patients who had inverted papilloma or squamous cell
carcinoma resected were eligible (coexistent inverted papilloma and squamous cell carcinoma
were excluded). Inclusion required tumor size of >1.5 cm and a preoperative MR imaging
with axial T1, axial T2, and axial T1 postcontrast sequences. Five well-established texture
analysis algorithms were applied to an ROI from the largest tumor cross-section. For a
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training dataset, machine-learning algorithms were used to identify the most accurate model,
and performance was also evaluated in a validation dataset. On the basis of 3 separate
blinded reviews of the ROI, isolated tumor, and entire images, 2 neuroradiologists predicted
tumor type in consensus.
Results: The inverted papilloma (n = 24) and squamous cell carcinoma (n = 22)
cohorts were matched for age and sex, while squamouscell carcinoma tumor volume was
larger (P = .001). The best classification model achieved similar accuracies for training
(17S squamous cell carcinomas, 16 inverted papillomas) and validation (7 squamous cell
carcinomas, 6 inverted papillomas) datasets of 90.9% and 84.6%, respectively (P = .537).
The machine-learning accuracy for the entire cohort (89.1%) was better than that of the
neuroradiologists’ ROI review (56.5%, P = .0004) but not significantly different from the
neuroradiologists’ review of the tumors (73.9%, P = .060) or entire images (87.0%, P = .748).
Conclusion: MR imaging-based texture analysis has the potential to differentiate
squamous cell carcinoma from inverted papilloma and may, in the future, provide incremental
information to the neuroradiologist.
4.3 Introduction
Inverted papilloma (IP) is an uncommon sinonasal tumor of ectodermal origin that
most commonly arises from the lateral nasal wall [106, 107]. In addition to its pattern of
locally aggressive behavior and propensity for post-operative recurrence, there is a tangible
association with malignancy, mostly squamous cell carcinoma (SCC). Although reports vary
widely in frequency, the rate of carcinoma is on the order of 10-15% and approximately
60-70% of these are synchronous [108, 109]. Although office-based endoscopic incisional
biopsy is safe, the sensitivity for the diagnosis of malignancy has been called into question
due to sampling error [110].
It can be useful to preoperatively identify SCC when coexistent with IP to guide biopsy,
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expedite surgery, and plan an oncologically sound resection. Although bone thinning and
remodeling without large areas of erosion on CT are more characteristic of IP than SCC,
this finding is imperfect because IP may also aggressively destroy bone, particularly when
contacting the walls of the sphenoid sinuses and floor of the anterior cranial fossa [111, 112].
Not surprising, FDG-PET has shown a higher mean standard uptake value for SCC compared
with IP, but significant overlap limits the clinical utility of PET [113]. To date, MR imaging
has the most promise in differentiating SCC from IP. Although early work initially found
no signature appearance on MR imaging for IP, alternating hypointense and hyperintense
bands on T2-weighted and contrast-enhanced T1-weighted sequences have become recognized
as a distinctive feature of IP and have been described as a convoluted cerebriform pattern
[111, 114–116]. As with any subjective finding, interpretive errors can occur, especially when
tumors are small or incompletely express the convoluted cerebriform pattern. Hence, a more
objective form of image analysis is desirable.
Texture analysis is a form of image processing that seeks to characterize complex visual
patterns by quantitatively identifying simpler but characteristic subpatterns. Within the
field of head and neck radiology, texture analysis has shown applicability in predicting the
p53 status of SCC, classifying SCC as human papilloma virus-related, predicting treatment
response in head and neck cancer, differentiating benign from malignant thyroid nodules,
and characterizing parotid tumors and structural changes after radiation therapy [117–125].
Because a large volume of data is generated when multiple texture analysis algorithms are
applied to MR imaging sequences, the statistical comparison of individual texture features
is of limited practical value; instead, a multifactorial data-driven analysis is necessary (ie,
“radiomics”). Therefore, the objective of this study was to determine whether MR imaging-
based texture analysis can differentiate sinonasal SCC from IP by using a multiparametric
machine-learning model. Model performance was additionally compared against qualitative
neuroradiologists’ interpretation to determine its potential for added clinical value.
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4.4 Methods
Figure 4.1: ROI placement. A 51-year-old man with an IP involving the right maxillary sinus.
Axial T2-weighted fat-suppressed MR imaging pulse sequence demonstrates the manual
placement of the largest rectangular ROI that would fit within the tumor margins on the
axial image with the greatest tumor cross-sectional area. The inset image in the lower right
corner is representative of the final 16x16 matrix that was derived from the ROI isocenter
and served as the input for texture analysis.
4.4.1 Subject Enrollment
The institutional review board at the authors’ institution approved this retrospective
study, and the need for informed con- sent was waived. The pathology data base was queried
to identify adult patients (18 years of age or older) who underwent resection of sinonasal IP
or SCC. Subjects enrolled from January 1, 2009, to December 31, 2014, were included in
the training dataset for model development, while those enrolled between January 1, 2015,
and July 1, 2016, composed the validation dataset. To ensure that only a single histologic
tumor type would be used for texture analysis, we excluded cases of coexistent IP and SCC.
Potential subjects were screened to determine which of them had a preoperative face MR
imaging available for review. The MRIs, which were performed on numerous scanners within
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the authors’ institution and at external facilities, had to be of diagnostic image quality. At
a minimum, the imaging had to include an axial T1-weighted MRI pulse sequence (T1),
an axial T2-weighted with frequency-selective fat suppression sequence (T2), and an axial
T1-weighted postcontrast MRI pulse sequence with frequency-selective fat suppression (T1C)
for texture analysis, with a section thickness of ≤ 5mm, an FOV ≤ 22cm, and a matrix
size of at least 256x192. No restrictions on additional MR imaging technical parameters
or type of gadolinium-based intravenous contrast were imposed, and studies were included
whether they were performed at 1.5T or 3T field strength. The electronic medical record
was reviewed for each potential case, and subjects were excluded if they had an intervention
for the sinonasal tumor, including biopsy, surgery, chemotherapy, or radiation therapy before
imaging. Subjects were further eliminated if the tumor did not have orthogonal transaxial
dimensions greater than 1.5x1.5 cm on at least 1 axial image.
4.4.2 Image Preparation and Texture Analysis
DICOM files containing the T1, T2, and T1C pulse sequences (also referred to as
“contrasts” for the purpose of texture analysis) were anonymized and encoded so that all
subsequent image analysis was blinded. To ensure uniformity for texture analysis, we
performed resampling and/or zero padding to generate images with an 18-cm FOV and a
256x256 pixel array and normalized image intensities to a dynamic range of 0-255. The
studies were then reviewed by a board-certified neuroradiologist with OsiriX (Version 6.5;
http://www.osirix-viewer.com). The borders of the tumor were manually traced on all
T1C images on which tumor was visible to generate an ROI-based cross-sectional area for
each image and an estimated tumor size by using the ROI volume function in OsiriX. On the
axial image with the greatest tumor cross-sectional area, the neuroradiologist inserted the
largest possible rectangular ROI that would fit within the tumor for all 3 sequences (Figure
4.1). To prevent the 2D texture analysis from being biased by tumor size, a computer script
determined the maximal square ROI that could fit within all manually drawn rectangular
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ROIs across all subjects and automatically positioned this smallest common square ROI at
the isocenter of each of the rectangular ROIs. The contents of this square ROI, with 16x16
pixels, served as the input for texture analysis.
Texture analysis of each ROI consisted of 3 first-order intensity-based features (mean,
standard deviation, and range of gray-level intensities) and features computed by using 5
widely available texture algorithms (all implemented in Python 2.7 programming language
[99], by using either custom-written code based on publications or open-source libraries as
noted):
1. Gray-Level co-occurrence Matrices (GLCM) is a widely applied method that uses
second-order statistics to assess the arrangement of similar gray-scale intensities within
an ROI [126]. GLCM evaluates how frequently a pair of intensity levels is identified
in an orientation based on a specified angle and radius. In the current study, the
co-occurrence matrix was determined for a distance of 1 pixel over 4 angular directions
(0◦, 45◦, 90◦, and 135◦). The mean and range for 13 rotationally invariant features
(including measures of homogeneity, entropy, angular/s moment, correlation, and
dissimilarity) were computed at each ROI for each MR imaging contrast [126].
2. Local Binary Patterns [127] evaluates the set of points within a fixed radius of a
specified voxel to determine in a binary fashion whether they are higher or lower in
intensity than neighboring voxels. Depending on the number of bitwise transitions
across this interrogated region, the local binary patterns can be classified as uniform
or nonuniform, and histograms of these data provide a measure of ROI uniformity. A
3-pixel radius was selected to complement the smaller scale patterns already assessed
by GLCM. A 12-bin histogram was used, resulting in 12 local binary pattern texture
features being calculated at each ROI for each MR imaging contrast.
3. Discrete Orthonormal Stockwell Transform (DOST) provides a rotationally invariant
multiresolution spatial-frequency representation of an image based on dyadic sampling
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of the Fourier representation of the image [91]. Ten DOST features were calculated at
each ROI for each MR imaging contrast.
4. Laplacian of Gaussian Histogram (LoGHist) is a convolution-based method to capture
the spectral composition of an image in intermediate scales not achievable with first-
and second-order statistics. Through the use of varying sizes of bandpass filters,
different scales of texture ranging from fine to coarse are highlighted [94].Gaussians
with 3 different values of (2.0, 4.0, and 6.0) were used to cover the range of fine-to-
medium-scale textures, and 18 LoGHist features were generated at each ROI for each
MR imaging contrast.
5. The Gabor filter banks (GFB) technique uses localized and linear filters to capture
details in various frequency resolutions [93]. Four different Gabor filters were rendered
by using 2 sigma levels (1.0 and 3.0) and 2 frequency levels (0.6 and 1.0). By calculating
the mean and standard deviation of the filtered ROI, we computed 8 GFB features at
each ROI for each MR imaging contrast.
Table 4.1: Patient demographic characteristics and tumor features
Sample Sex Tumor Volume Tumor Stagea
Study Group Size (Female/Male) Age (yr) (cm3) T1 T2 T3 T4
IP training 16 4:12 58.0 ± 12.1 21.2 ± 17.7 1 3 10 2
IP validation 6 1:5 58.2 ± 15.3 22.0 ± 6.9 1 1 3 1
IP combined 22 5:17c 58.1 ± 13.1d 21.4 ± 15.5e 2 4 13 3
SCC training 17 4:13 54.0 ± 13.5 55.8 ± 40.5 0 1 4 12
SCC validation 7 1:6 54.6 ± 9.4 43.5 ± 27.9 0 1 2 4
SCC combined 24 5:19c 54.2 ± 12.5d 52.2 ± 37.7e 0 2 6 16
a Data are presented separately for the training and validation sets and also as a single combined cohort
for each tumor.
b Tumor stage represents the Krouse staging system [128] for IP and the American Joint Committee on
Cancer staging [129] for SCC.
c Fisher’s exact test, P = .578.
d Two-sample t test, P = .317.
e Two-sample t test, P = .001.
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4.4.3 Neuroradiologists’ Review
Using OsiriX, 2 neuroradiologists with 25 and 28 years of experience, respectively,
performed a blinded review to reach a consensus diagnosis of IP or SCC for each case. This
was performed during 3 separate rounds of image review, each of which was randomized and
completed in the following order:
1. ROI: For the T1, T2, and T1C series, the neuroradiologists exclusively reviewed the
16x16 square ROIs that had been used for texture analysis.
2. Tumor: On all images in the T1, T2, and T1C series, the data outside the tumor
margins were zero-filled so that the neuroradiologists could only base their assessment
on the intrinsic appearance of the tumor without information regarding tumor location
and invasive behavior.
3. Image: The neuroradiologists were able to review the unaltered T1, T2, and T1C
imaging datasets in their entirety.
4.4.4 Machine Learning and Statistical Analysis
Open-source R statistical and computing software (http://www.r- project.org) was
used to perform the analyses and classification. Hypothesis tests were 2-sided, and statistical
significance was defined as P < 05. The comparison of subject demographics and tumor
size between IP and SCC was performed by using a 2-sample t test for subject age and
tumor volume and a Fisher exact test for sex. The 2-sample t test was used for a univariate
comparison of texture features between IP and SCC before the application of machine-
learning methodology, and P values were corrected for multiple comparisons by using the
false discovery rate [103].
A total of 231 texture features were calculated for each case (77 texture features per MR
imaging contrast). To reduce the dimensionality of the texture features and increase the
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generalizability of the predictive model for the training dataset, we used principle component
(PC) analysis [130–132]. PCs, which are linear combinations of features, were identified
separately for each texture algorithm and MR imaging contrast. Those PCs that sufficiently
accounted for 90% of the texture feature variability were selected for further processing.
Three commonly described classification algorithms, Diagonal Linear Discriminate Analysis,
Support Vector Machines, and Diagonal Quadratic Discriminate Analysis, were conducted
on the basis of the selected PCs in an attempt to differentiate SCC from IP [35, 133, 134].
Support vector machine model was build using a radial basis function kernel with coefficient
value of 1 and gamma parameter equal to 1/numberoffeatures. The setting used for
quadratic discriminant analysis was no priors on classes and threshold of 0.0001 for rank
estimation. Sequential forward feature selection identified the image-based PCs that yielded
the greatest accuracy [130, 131]. In developing the classification model, we initially selected
the PC with the largest discriminatory power and incorporated additional PCs that improved
model accuracy in an iterative fashion until incremental gains in accuracy were 1%.
Classification accuracy was determined by using leave-one-out cross-validation, in which
all samples except for 1 were used, while the left-out sample served as the test case with
which to assess classification accuracy [45]. This process was repeated until all samples in
the training dataset had served as the test case, and the overall cross-validation accuracy
was the averaged accuracy. The most accurate classification model was applied in a blinded
fashion to the validation dataset, and the diagnostic performance of the model was assessed.
Model performance accuracies between the training and validation datasets and between the
best classification model and neuroradiologists’ review were compared by using a 2-tailed
test of population proportion.
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Figure 4.2: Heat map showing MRI texture feature significance in distinguishing tumor type.
Univariate analysis compared pathology status (SCC vs. IP) with MRI-texture features.
Color maps show the false discovery rate-adjusted P-values of two-sample t test. MRI
contrasts (pulse sequences) are listed above the columns, and MRI-based texture features
are listed in rows. DOST features 0 to 9 correspond with low to high frequency patterns.
LBP 0 to 11 are the normalized bin counts in the LBP histogram. The reader is referred to
the Methods section for additional details about the features.
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4.5 Results
Thirty-three subjects were included in the training set, 16 IPs and 17 SCCs, while the
validation set consisted of 6 IPs and 7 SCCs (Table 4.1). The patients were similarly matched
for age and male-predominant sex. Mean tumor volume was larger for SCC than IP (P <
.001).
Individual features derived from the 5 different texture analyses across all 3 MR imaging
contrasts (T1, T2, T1C) were initially evaluated in a univariate fashion to look for significant
differences between the IP and SCC groups (Figure 4.2). The greatest number of texture
features showing statistically significant differences were derived from the DOST and GFB
texture analyses.
Model performance for the training and validation datasets is presented in Table 4.2.
Following PC analysis and machine-learning classification, the predictive classifier with the
best classification result was using support vector machine, yielding 90.9% accuracy for the
training dataset. The 84.6% accuracy of the validation dataset did not significantly differ
from that achieved in the training dataset (P = .537). When we combined the training
and validation cohorts (n = 46), the accuracy achieved by texture analysis (89.1%) was
significantly better than that of the ROI-based neuroradiologists’ review (Table 4.3, 56.5%,
P = .0004) and showed a trend toward improved accuracy over neuroradiologists’ review of
the entire tumor (73.9%, P = .060). Texture-analysis accuracy was not significantly different
from that of the neuroradiologists’ reviewing the entire unaltered images (87.0%, P = .748).
Relative contributions to model accuracy from each texture analysis algorithm and MR
imaging contrast are presented (Figure 4.3). The most significant texture features were
derived from T1C-GFB, T1-GLCM, and T1-DOST (Figure 4.4).
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Table 4.2: Diagnostic performance of machine-learning classification on training and validation
datasets
Tumor Type
Model Prediction (Pathologic Diagnosis)
for Training Dataset SCC IP
SCC 16 2 Accuracy 90.9%a
Sensitivity 94.1%
IP 1 14 Specificity 87.5%
PPV 88.9%
Total 24 22 NPV 93.3%
Model Prediction
for Validation Dataset
SCC 6 1 Accuracy 84.6%a
Sensitivity 85.7%
IP 1 5 Specificity 83.3%
PPV 85.7%
Total 7 6 NPV 83.3%
Model Prediction
for Entire Cohort
SCC 22 3 Accuracy 89.1%
Sensitivity 91.7%
IP 2 19 Specificity 86.4%
PPV 88.0%
Total 24 22 NPV 90.5%
Note:–NPV and PPV indicate negative and positive predictive values, respectively.
aWith a 2-tailed test of population proportion, the accuracies for the training
and validation datasets were not significantly different (P = .537).
4.6 Discussion
MR imaging has long been recognized as the most useful technique with which to
distinguish sinonasal SCC from IP. Most of the prior work focused on a qualitative imaging
appearance known as the “convoluted cerebriform pattern” [111, 114–116, 135, 136]. Although
this pattern has a high level of sensitivity for IP, it is not entirely specific. As an example,
Jeon et al. [113] evaluated the performance of the convoluted cerebriform pattern in 30
patients with IP relative to 128 patients with sinonasal malignancies and reported a sensitivity
of 100%, specificity of 87%, positive predictive value of 64%, negative predictive value of
100%, and accuracy of 89%.
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Figure 4.3: Relative contributions to model accuracy. The bar graph demonstrates the
accuracy attributable to PCs derived from T1C-GFB, T1-DOST, and T1-GLCM (upper
pane) to the 90.91% overall model accuracy. Across all texture algorithms, the contribution
to total model accuracy was derived predominantly from T1C, with minor contributions
from T1 and no input from T2 (lower pane).
Texture analysis integrated into a machine-learning model was able to classify SCC and
IP with an accuracy on par with the previously published results based on the convoluted
cerebriform pattern. It is also similar to the best consensus neuroradiologists’ interpretation
in the current study. However, this technology is meant to supplement a neuroradiologist’s
interpretive skills rather than compete with them. In clinical practice, a diagnosis is rendered
by synthesizing all available data that include not only intrinsic tumor appearance but also
other imaging features such as site of origin, tumor size, ex-trasinonasal extension, and
tumor margins. Indeed, the current results support a neuroradiologist’s accuracy improving
for differentiating sinonasal IP and SCC as more imaging information is made available.
On the basis of a 16x16 ROI, the texture-based machine-learning model outperformed the
accuracy of the neuroradiologists (P = .0004). In terms of assessing the intrinsic tumor
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Table 4.3: Diagnostic performance of texture analysis with machine learning compared with
neuroradiologists’ review for the differentiation of SCC from IP a
Analysis Method Accuracyb Sensitivity Specificity PPV NPV
Texture analysis with 89.1% 91.7% 86.4% 88.0% 90.5%
machine learning
Neuroradiologist’s 56.5% 54.2% 59.1% 59.1% 54.2%
review, ROI (P = .0004)
Neuroradiologist’s 73.9% 75.0% 72.7% 75.0% 72.7%
review, tumor (P = .060)
Neuroradiologist’s 87.0% 91.7% 81.8% 84.6% 90.0
review, image (P = .748)
a Results are shown for the entire cohort (22 IPs, 24 SCCs) and reflect the best classification
model. The labels for the neuroradiologists’ assessment indicate whether they reviewed the
16x16 ROI (ROI), tumor alone (tumor), or entire images (image).
b P values represent comparison of texture analysis with machine learning against each
neuroradiologist’s review using a 2-tailed test of population proportion.
appearance, texture analysis stands to provide incremental benefit when human pattern
recognition becomes most limited, and this can occur with a small tumor. For example,
Maroldi et al. [111] found it more challenging to recognize the convoluted cerebriform pattern
on T2-weighted images for tumors of 2 cm. While tumors smaller than 1.5x1.5 cm were
excluded from enrollment in the current study, the final processed ROIs were only 1.125x1.125
cm.
Because small noninvasive sinonasal tumors are not universally imaged with MR imaging,
the greatest potential benefit for texture analysis might be in detecting a small focus of
SCC within a larger IP to expedite patient management. Accurately assessing small regions
would be a prerequisite for the detection of such tumor heterogeneity. The potential for
interpretive error is greatest when a small focus of SCC exists within a much larger IP and
goes unrecognized because a convoluted cerebriform pattern is still present. Indeed, this
pattern of a “partial” convoluted cerebriform pattern has been described [111, 114, 137].
Likewise, necrosis, recognized as nonenhancing tissue on contrast-enhanced MR imaging, is
associated with SCC but may not be apparent when a small focus of SCC coexists with an
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Figure 4.4: PC loading. The model with the greatest accuracy for discriminating SCC from
IP was derived from T1C-GFB, T1-GLCM, and T1-DOST texture features (right). For the
individually specified texture features (left), PC loadings are graphically represented, and
larger values in the PC loading indicate greater significance in the final model.
IP [114, 115, 137]. A future goal for texture analysis of a mixed tumor containing both IP
and SCC is to assist with interpretation by highlighting areas that are most suspicious for
SCC.
Texture analysis can also extract useful features from images that have been traditionally
neglected by the human eye. The convoluted cerebriform pattern has been historically
described on T1-weighted postcontrast and T2-weighted sequences [111, 114–116, 135–137].
However, noncontrast T1-weighted MR imaging has received no attention to date, to our
knowledge. The texture analysis in the current study found more significant features for
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T1 than T2 on a univariate basis (Figure 4.2). Although T1-DOST and T1-GLCM made a
minority contribution to the final model, no T2 features contributed to final model accuracy
(Figure 4.3).
For MR imaging, it has been suggested that texture analysis models may not effectively
translate across different imaging protocols and scanner platforms [138, 139]. Certainly,
this possibility would make such results clinically meaningless because a new model would
have to be created for each scanner running a unique protocol. Fruehwald-Pallamar et
al. [140] concluded that texture analysis is not practical for differentiating malignant and
benign tumors of the head and neck when using different protocols on different MR imaging
scanners. However, their cohort was very heterogeneous, containing numerous types of
benign and malignant lesions. The subjects for the current study were accrued during a long
period and were not imaged with a common scanner and protocol. Nevertheless, an accurate
texture-based model was achieved that performed similarly in the training and validation
datasets. At least for the context of sinonasal IP and SCC, this outcome holds promise for
reproducibility across scanner platforms.
The current study is limited, given its retrospective nature and small sample size. Hence,
the high accuracy for the differentiation of SCC from IP with texture analysis is not meant
to represent the performance of an established diagnostic imaging test. Instead, these results
merely confirm the feasibility of this technique for distinguishing these 2 tumor types. In
showing proof of concept, a 2D ROI-based analysis was used to confirm discriminatory ability
with a limited data sample. Moreover, because SCC tends to be a larger tumor than IP on
average, this approach eliminated the potential for falsely finding texture differences on the
basis of relative oversampling of a larger tumor. Future directions will include the refinement
of the texture analysis pipeline into a volumetric tool with the objective of highlighting foci
of SCC when it is coexistent with IP. This will need to be studied prospectively to ensure
that the histopathologic analysis can be accurately coregistered to MR imaging.
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4.7 Conclusion
With MR imaging-based texture analysis, a machine-learning model for the differentiation
of sinonasal SCC and IP achieved accuracy comparable with both neuroradiologists’ interpre-
tation and previously published reports on the convoluted cerebriform pattern. Because the
classification model was significantly more accurate than the neuroradiologists’ interpretation
for a small ROI, texture analysis has the potential to provide incremental benefit to the
neuroradiologists’ interpretation, particularly in cases of small or heterogeneous tumors.
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Chapter 5
VALIDATION STUDY II: COMPUTER-AIDED DIAGNOSIS OF
CONTRAST-ENHANCED SPECTRAL MAMMOGRAPHY – A FEASIBILITY STUDY
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5.2 Abstract
Objective: To evaluate whether the use of a computer-aided diagnosis contrast-enhanced
spectral mammography (CAD-CESM) tool can further increase the diagnostic performance
of CESM compared with that of experienced radiologists.
Materials and methods: This IRB-approved retrospective study analyzed 50 lesions
described on CESM from August 2014 to December 2015. Histopathologic analyses, used
as the criterion standard, revealed 24 benign and 26 malignant lesions. An expert breast
radiologist manually outlined lesion boundaries on the different views. A set of morphologic
and textural features were then extracted from the low-energy and recombined images.
Machine-learning algorithms with feature selection were used along with statistical analysis
to reduce, select, and combine features. Selected features were then used to construct a
predictive model using a support vector machine (SVM) classification method in a leave-
one-out cross-validation approach. The classification performance was compared against the
diagnostic predictions of 2 breast radiologists with access to the same CESM cases.
Results: Based on the SVM classification, CAD-CESM correctly identifies 45 of 50
studies in the cohort, resulting in overall accuracy of 90.0%. Detection rate for the malignant
group was 88.4% (3 FN cases) and 91.6% for the benign group (2 FP cases). Compared with
the model, radiologist 1 had an overall accuracy of 78.0% and detection rate of 92.3% (2 FN
cases) and 62.5% (9 FP cases) for the malignant and benign groups, respectively. Radiologist
2 had an overall accuracy of 86.0%, with detection rate of 100.0% and 70.8% (7 FP cases)
for the malignant and benign groups, respectively.
Conclusions: The results of our feasibility study suggest that a CAD-CESM tool
can provide complementary information to radiologists, mainly by reducing the number of
false-positive findings.
Keywords: breast cancer, contrast enhanced digital mammography (CEDM), contrast
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enhanced spectral mammography (CESM), quantitative image analysis (QIA), texture
analysis, computer aided diagnosis (CAD)
5.3 Introduction
The primary goal of breast cancer screening is to reduce subsequent breast cancer
mortality through early detection. However, FFDM’s overall sensitivity of 75% to 85%
[141] may be as low as 30% to 60% for dense-breasted women [142]. Additionally, many
women receive false-positive diagnoses because the positive-predictive value of FFDM is 18%
to 31% [143]. These women undergo unnecessary supplemental imaging and, occasionally,
invasive procedures to evaluate the suspicious findings. Patient stress, inconvenience, cost,
and potential for harm because of these additional procedures are concerning. Overall,
supplemental imaging and biopsy affect 3.2 million American women at an estimated cost of
$2.8 billion [144].
Dual-energy contrast-enhanced spectral mammography (DE-CESM or CESM) (also called
dual-energy contrast-enhanced digital mammography [DE-CEDM]) improves the accuracy of
breast cancer diagnosis [145]. CESM generates a low-energy mammographic image along
with a recombined contrast-enhanced image, reflecting contrast accumulation within a breast
(Figure 5.1). Breast regions with increased or leaky vasculature, two common characteristics
of neoplasms, can be identified using intravenously administered, iodinated-contrast material,
thus improving lesion detection and characterization [146]. Although studies have shown
that CESM is superior to FFDM, specificity is estimated to be 58% to 70% [147], leaving
room for further improvement in diagnostic accuracy, for example, by applying quantitative
image analyses.
Quantitative image analysis is a topic of active research that includes well-established
applications like computer-aided diagnosis (CAD) algorithms. CAD algorithms, when coupled
with traditional mammography, have shown promise for identifying suspicious breast lesions
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Figure 5.1: CESM images. A 64 year-old woman with a malignant appearing lesion on the
left breast. This was later shown via biopsy to be invasive ductal carcinoma (IDC). Each
lesion was captured in 2 views with 2 images per view, low-energy (LE) and recombined
image. The green contours are the lesion contours marked by the radiologist.
[148]. These algorithms have evolved and are improved by leveraging large datasets generated
from high-throughput sequencing experiments [149]. However, no studies thus far have
evaluated the use of CAD algorithms in CESM.
Recently, there has been some interest in the use of texture features to distinguish
benign and malignant lesions on magnetic resonance [150] and mammographic imaging
[151]. We hypothesized that lesion texture and shape features can often capture often-missed
information regarding the characteristics of a tumor and can provide details that have
prognostic or diagnostic value [13]. These texture features describe intensity distributions
within the lesion and capture spatial and spectral frequency patterns, as well as characterize
the relationships between different intensity levels within the lesion. Some of these features
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might not be visually apparent to the radiologists and therefore have the potential to
complement the diagnostic skillset of radiologists. The purpose of our current study was to
evaluate a prototype CAD-CESM tool, using texture and morphologic analysis to differentiate
benign and malignant breast lesions.
5.4 Material and Methods
5.4.1 Study Population
The study was considered exempt by the Institutional Review Board (IRB). We ret-
rospectively reviewed CESM examinations on a Selenia mammography system (Hologic,
Bedford, MA). The examinations were performed between August 1, 2014, and December 31,
2015. Informed consent was obtained from all patients having a BI-RADS (Breast Imaging
Reporting and Data Systems) [152] classification of 4 and 5 in a preexisting IRB-approved
study to determine if CESM could lower the false-positive biopsy rates in mammography.
As part of the aforementioned study, the radiologist counseled patients on the risks and
benefits of biopsy and CESM. CESM was offered as an adjunct, not as an alternative to
the recommended breast biopsy. The patient was informed that CESM might increase or
decrease the level of suspicion of a lesion and might show additional suspicious areas. CESM
was performed before the biopsy, typically on the diagnostic examination day or on the day
of the biopsy.
The cohort for the current study included examinations that met the following criteria:
(1) a diagnostic mammogram that received a BI-RADS rating of 4 or 5 and (2) studies that
corresponded with available pathologic results from a surgical or image-guided biopsy. We
limited the cohort to BI-RADS 4 and 5 lesions because the analysis required the criterion
standard of lesion pathology. We identified 50 studies that met the above inclusion criteria,
comprising 24 benign and 26 malignant, biopsy-proven lesions (Table 5.1). We analyzed 1
lesion per patient. If a patient had multiple enhancing lesions, the annotating radiologist
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selected the largest lesion to ensure the best feature section. Statistical analysis was performed
in Python 2.7.0 environment [99] using the open-source SciPy library [101].
5.4.2 CESM Image Acquisition Protocol
The patients were seated in the mammography suite to minimize vasovagal episodes.
They received contrast via a single-lumen power injector: 1.5 mL/kg of Omnipaque 350
(GE Healthcare, Inc, Princeton, NJ) at a rate of 3 mL/second. We waited 2 minutes
following the injection, compressing the breast and obtaining images exactly 2 minutes
after contrast administration. The examination began with the mediolateral oblique (MLO)
view of the affected breast because this view encompasses the most breast tissue. Next,
images on the craniocaudal (CC) view were acquired. Image acquisition was completed
within 7 minutes. The low-energy and recombined images were immediately available to an
interpreting radiologist after the study.
5.4.3 Segmentation of Lesions and the Regions of Interest
All DICOM (Digital Imaging and Communications in Medicine) images were transferred to
a database and loaded into the open source image processing tool OsiriX (OsiriX Foundation,
Geneva, Switzerland) [153]. DICOM images were anonymized and prepared for blinded
reading by a radiologist. A fellowship-trained breast radiologist with over 8 years of imaging
experience interpreted the mammogram blindly and used the OsiriX tool to outline lesion
contours. Contours were drawn on the CC and MLO recombined views for each patient.
These contours were then cloned onto low-energy images. All lesions were visible in both
views. For texture analysis, we required a fixed-sized rectangular area entirely contained
within each lesion contour. From each enclosed region, we selected a 32x32 pixel area at
the centroid of each rectangle as the region of interest (ROI) for feature extraction (Figure
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Table 5.1: Summary of the study population
Biopsied Lesion N (%)
All lesions 50
Benign cases 24 / 50 (48.0%)
- Fibroadenoma 6 / 24 (25.0%)
- Fibrosis 5 / 24 (20.8%)
- Intraductal papilloma 2 / 24 (8.3%)
- PASH 1 / 24 (4.2%)
- Fat necrosis 1 / 24 (4.2%)
- Sclerotic intraductal papilloma 1 / 24 (4.2%)
- Cyst 1 / 24 (4.2%)
Malignant cases 26 / 50 (52.0%)
- Ductal carcinoma in situ 6 / 26 (23.1%)
∗ Grade 1 1 / 26 (3.8%)
∗ Grade 2 1 / 26 (3.8%)
∗ Grade 3 4 / 26 (15.4%)
- Invasive ductal carcinoma 17 / 26 (65.4%)
∗ Grade 1 5 / 26 (19.2%)
∗ Grade 2 6 / 26 (23.1%)
∗ Grade 3 6 / 26 (23.1%)
- Invasive lobular carcinoma 3 / 26 (11.5%)
∗ Grade 1 1 / 26 (3.8%)
∗ Grade 2 2 / 26 (7.7%)
Abbreviation: PASH, PseudoAngiomatous Stromal Hyperplasia.
5.2). The size of the ROI was selected based on the size of the smallest lesion in the cohort,
excluding areas with post biopsy image change.
5.4.4 Feature Computation
A set of four shape features were extracted per lesion contour [100]: shape bending
energy, shape compactness, shape entropy, and shape radial-length ratio. Thus, 8 shape
features were extracted per lesion (4 features/contour, 2 contours per lesion). Next, we used
statistical and spectral methods [1, 17, 56] to measure texture at various spatial and spectral
scales of the lesions. Feature calculation was performed using an in-house pipeline written
in Python 2.7.0 [99]. A total of 236 texture features were computed from each subregion.
Texture features included 3 from raw-image intensity, 26 from Gray Level Co-occurrence
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Figure 5.2: Regions of interest for shape and texture analysis. 61 year-old woman with a
malignant appearing lesion on the right breast. (a) view: Mediolateral-Oblique or MLO,
low-energy image (LE) - (b) view: Cranial-Caudal or CC, Low Energy image (LE), (c) view:
MLO, recombined image and (d) view: CC, recombined image. ROIs are identical for the
low-energy and contrast-enhanced images on each view. Shape features are extracted from
contours (green) and texture features are extracted from a rectangular area inside each
contour (red).
Matrices (GLCM) [126], 18 from Laplacian-of-Gaussian Histograms (LoGHist) [94], 126 from
a Gabor Filter Banks (GFB) [93], 48 from Local Binary Patterns (LBP) [127], and 15 from
the Discrete Orthonormal Stockwell Transform (DOST) [91]. Detailed descriptions of the
texture features are provided in Table 5.2.
5.4.5 Feature Selection and Statistical Analysis
Feature selection, analysis, and model generation were performed using a Python-based
platform developed in-house utilizing the Scikit-learn package [102]. We used a sequential
forward feature selection (SFFS) approach in conjunction with quadratic discriminant analysis
[104] to identify the most discriminating features. SFFS starts with an empty set of features
and gradually adds features that offer minimal redundancy but maximal relevance. The
setting used for quadratic discriminant analysis was no priors on classes and threshold of
0.0001 for rank estimation.This approach was repeated 100 times with a random-sampling
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scheme to reduce training bias and improve model generalizability. In each trial, we randomly
selected one-third of the benign and malignant samples and fed the combined samples to
SFFS. The 10 most frequently appearing features among all iterations were selected for
further analysis. Inclusion of more features did not improve classification accuracy.
To simplify results of the analysis, features resulting from a shared-texture method
(eg, GLCM, GFB) were combined using principal component analysis (PCA) [104]. PCA
creates linear combinations of features called principal components (PCs). One to three PCs
were generated per feature group, sufficient to describe 90% of the feature variability. The
final set of features was tested for statistical significance by using a 2-sample t test, with a
P-value of less or equal to 0.05 considered significant. The significant features were used for
classification.
5.4.6 Machine Learning Classification
The statistically significant features, described above, were provided to a Support Vector
Machine (SVM) classifier 20 for construction of a lesion malignancy model. SVM model was
build using a radial basis function kernel with coefficient value of 1 and gamma parameter
equal to 1/numberoffeatures. We utilized a leave-one-out cross-validation (LOOCV)
technique [104] for model construction and estimation of classification performance. LOOCV
iteratively sets aside 1 sample from the dataset as the test sample and uses the remaining
samples as the training set for model development. The model is validated on the test sample
in each trial. This process is repeated until every sample serves as the test sample. We used
this approach to predict the malignancy status of the lesions. The predicted diagnosis across
all test samples was used to estimate performance measures, such as accuracy, sensitivity,
specificity, and area under the receiver operating characteristic (ROC) curve.
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Table 5.2: Summary of the texture features used for breast lesion characterization
Method Type of
features
Details and Settings
Raw intensity Statistical Mean, range, standard deviation of the ROI
scaled intensities before scaling the dynamic
range to [0,255]
Gray Level Co-occurrence Ma-
trices (GLCM) [126]
Statistical Mean and range of 13 GLCM features at 4 angles
(radius of 1).
Discrete Orthonormal Stock-
well Transform (DOST) [91]
Spectral Rotationally invariant dost features for all possi-
ble dyadic frequency bands insidethe ROI. With
the ROI with the size of 32x32, 15 Dost features
were extracted.
Laplacian of Gaussian His-
togram (LoGHist) [94]
Spectral Kurtosis, skewness, standard deviation, aver-
age intensity, entropy and uniformity of the his-
togram resulting from convolutions of band pass
filtersand the ROI. Band pass filter sigma range
(2.0, 4.0, 6.0).
Local Binary Patterns (LBP)
[94]
Statistical Values of histogram bins generated from inten-
sity patterns found within the ROI. The intensity
patterns are categorized into ’uniform’ and ’non-
uniform’ based on the number of bit-wise tran-
sitions from 0 to 1 or vice versa within patches
within the ROI. Radius of patches: (3.0, 5.0, 8.0,
12.0).
Gabor Filter Banks(GFB)
[93]
Spectral Gabor filters (sigma: [1.0 - 5.0], increments of
0.5, frequency: [0.2 - 0.8] increments of 0.1) were
used to focus on different frequency resolution
in the ROI. Mean and standard deviation of
intensities of each filtered image was used as a
GFB feature.
5.4.7 Comparative Human Reader study
Two breast-fellowship-trained radiologists with 5 years of total radiology experience and
6 months experience interpreting CESM images, not involved in other aspects of the study,
reviewed the lesions to provide a non-computer-aided prediction of lesion pathology. Each
lesion location was made apparent to the radiologist with the quadrant location written
next to the case number. The images were reviewed according to standard diagnostic
mammography workflow at our institution. Both breasts in the standard CC and MLO
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views were read first as a diagnostic mammogram on dedicated Hologic workstations (and,
if needed, associated ultrasound images) and decided on as a malignant or benign lesion.
Next, the CESM images were reviewed independently by the readers and designated as
malignant or benign based on low-energy and recombined images. The readers were blinded
to the final pathology of the findings. No additional clinical information was provided to the
readers. Next, performance measures (accuracy, sensitivity, and specificity) of each reader
were calculated. The performance measures of the readers were compared to the performance
measures of our automated model.
5.5 Results
The average age of patients was 57.1 years (52.2 years, patients with benign lesions; 61.9
years, patients with malignant lesions). The age difference between the 2 groups (9.7 years)
was significant (P<.05). Twenty-six (52%) of the 50 biopsied lesions were diagnosed with
breast cancer at histopathology. The remaining 24 (48%) lesions were diagnosed with benign
pathology after core needle biopsy (Table 5.1).
Table 5.3 compares the performance measures of human readers and the computational
model. Reader 1 provided a sensitivity of 92.3% (2 false-negatives) and a specificity of 62.5%
(9 false-positives). Overall accuracy for Reader 1 was 78.0%. Reader 2 provided a sensitivity
of 100.0% (0 false-negatives) and a specificity of 70.8% (7 false-positives). Overall accuracy
for Reader 2 was 86.0%.
Differences between CAD-CESM and the readers are shown in Table 5.3. CAD-CESM
provided a sensitivity of 88% (3 false-negatives from 26 malignant cases). Two false-negative
results were invasive ductal carcinoma, and 1 was ductal carcinoma in situ. The false-negative
lesions ranged from 7 to 12 mm in diameter. CAD-CESM provided a specificity of 92% (2
false-positives from 24 benign cases). Overall, CAD-CESM accuracy was 90%. The differences
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Figure 5.3: Benign lesions misclassified by the radiologists. Three benign lesions (red arrows)
for which the label ’malignant’ was assigned by the blinded human readers but not by
the machine-learning developed quantitative model. Lesions are presented on the digital
subtraction (DES) images Mediolateral-Oblique (MLO) views. The Reader’s descriptions for
these cases were as follows: (a) multiple avidly enhancing lesions, (b) avidly enhancing mass,
satellite lesions, (c) obscured margins, not well defined.
Table 5.3: Exact McNemar’s test between CESM and Reader 1/Reader 2
Sensitivity Specificity Accuracy
Denominator Malignant (N = 26) Benign (N = 24) Overall (N = 50)
CESM 88% 92% 90%
Reader 1 92% 63% 78%
Reader 2 100% 71% 86%
Pvalue1 a >.99 0.016 0.109
Pvalue2 b NA 0.063 0.726
Abbreviation: CESM, Contrast-Enhanced Spectral Mammography.
a Comparing CESM and Reader 1.
b Comparing CESM and Reader 2. Pvalue is NA because of 0 cell.
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between CAD-CESM and the radiologists were statistically significant for reader 1 specificity
(P=.016). The readers were marginally superior to the model in detecting malignant cases
(0 and 2 misdiagnosed malignant cases for radiologists compared with 3 for the model). In
comparison, benign cases were detected more successfully using the quantitative model. 7
and 9 benign cases were diagnosed as malignant by radiologists compared with only 3 for the
model. Among the misclassified benign lesions by the readers, 3 cases were identical (Figure
5.3). The readers described these lesions using BI-RADS lexicon terms such as “obscured
margin”, “spiculated margin”, “distortion”, and “avidly enhancing”, which typically portends
a malignant diagnosis. The 3 lesions misclassified by the radiologists were, in fact, benign
cellular fibroadenoma, pseudoangiomatous stromal hyperplasia (PASH), and fibrosis.
Table 5.4 shows the list of features selected by the SFFS process. Among the selected
10 features, 7 were extracted from the recombined image, 1 from a low-energy image; 2
were selected from the lesion shape features. After feature selection, PCA was used to
combine the GFB, GLCM, DOST, and LoGHist texture features. Figure 5.4, A shows the
result of univariate analysis (P<.05) on the texture PCs and morphology features. Four
texture features survived the threshold of statistical significance, including 2 Gabor PCs
(combination of the standard deviations of features at high (f=0.8) and medium (f=0.4)
frequencies), 1 GLCM PC (combination of GLCM angular second moment, a measure of
homogeneity of the ROI, and GLCM difference variance), and 1 medium-frequency content
DOST feature. Among the morphology features, shape radial-length ratio corresponding to
irregularity of lesion shape was also identified as statistically significant.
The CESM-CAD malignancy model was constructed using 3 of the 5 statistically signifi-
cant features described above. The 3 features were Gabor PC2, Gabor PC3 – both texture
features extracted from the recombined images – and the morphology feature for lesion
radial-length ratio. The area under the ROC curve was 0.95. Figure 5.4, (B, C) shows the
quantitative model ROC curve, as well as the contributions of shape and texture features to
the model accuracy.
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Table 5.4: Frequently selected features in repeated sequential forward feature selection
algorithm on random samples
CESM
Image and
View
Feature Name Description
MLO, DES Standard deviation of Gabor
filter sigma =1.0, frequency =
0.7
Spectral texture feature corresponding to smaller
kernels that are sensitive to higher frequencies.
MLO, DES Standard deviation of Gabor
filter sigma = 3.0 frequency =
0.4
Spectral texture feature corresponds to kernels
that are sensitive to medium frequencies.
CC, DES Standard deviation of Gabor
filter sigma = 3.5 frequency =
0.8
Spectral texture feature corresponds to smaller
kernels that are sensitive to higher frequencies.
CC, LE Dost5 Spectral texture feature corresponding to
medium level frequencies.
CC, DES Dost3 Spectral texture feature corresponding with low
to medium frequencies.
MLO, DES GLCM Angular Second Mo-
ment
Statistical texture feature, measure of orderliness
in intensity values of neighboring pixels.
MLO, DES GLCM Difference Variance Statistical texture feature, measure of uniformity
in the intensity of neighboring pixels.
MLO, DES LoGHist Entropy with sigma
= 4.0
Spectral Texture feature, measure of entropy of
medium frequency band-pass filters.
MLO Shape entropy Morphology feature, Measure of predictability of
the lesion’s radial length a.
CC Shape radial length ratio Morphology feature, Ratio of minimum to maxi-
mum radial length a.
Key: CC, CranioCaudal; CESM, Contrast-Enhanced Spectral Mammography; DOST, Disc-
rete Orthonormal Stockwell Transform; GFB, Gabor Filter Banks; GLCM, Gray Level Co-occurrence
Matrices; LE, Low Energy; LoGHist, Laplacian-of-Gaussian Histogram; MLO, MedioLateral Oblique.
aRadial length = distance of boundary points from the center.
5.6 Discussion
The moderate specificity of mammography might result in additional imaging exams,
costs, and patient anxiety, and may cause avoidable breast biopsies. CESM was introduced
in 2011 to improve the diagnostic accuracy of breast imaging through mammography [154].
Although CESM is superior to FFDM, its specificity reaches a maximum of approximately
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70% [155]. Therefore, CAD tools might be used as an adjunct to radiologists’ assessments. In
this study, we aimed to evaluate the performance of a CAD-CESM tool based on quantitative
morphology and texture features extracted from lesions on the recombined CESM images.
We showed that by using this tool, the accuracy of CESM could be further improved when
compared with that of 2 experienced radiologists, especially regarding specificity of this
diagnostic test.
CESM is a promising imaging technique, which provides information from standard
digital mammography combined with enhancement characteristics related to underlying
neoangiogenesis. CESM has been reported to offer improved sensitivity, specificity, and
accuracy compared with conventional mammography [156]. Cheung et al. [144] investigated
the performance of CESM vs mammography in dense breasts. Their results suggested that
using CESM improves diagnosis by 21.2% in sensitivity, 16.1% in specificity, and 12.8% in
overall accuracy. Tagliafico et al. [147] recently summarized the diagnostic performance of
CESM in a systematic review of 8 eligible studies. The pooled sensitivity of CESM was 98%
(95% CI, 96%-100%); with a pooled specificity being moderate at 58% (95% CI, 38%-77%).
This moderate specificity is mainly explained by a preponderance of data from a Polish
study group, which showed very poor diagnostic accuracies, even for FFDM. When the
results of the review are recalculated with the results from the Polish group removed, the
specificity increases to 78% (95% CI, 56%-90%). CAD tools might aid in further improving
the specificity of CESM, preferably while not decreasing the already high sensitivity of
CESM.
In our study, the model of the CAD-CESM tool was constructed by using lesion-shape
irregularity and spectral texture features from an ROI. Lesion shape is one of the primary
diagnostic factors used by radiologists. In fact, radiologists describe the morphology of lesions
on imaging reports based on criteria suggested by BI-RADS shape vs margin [152]. The shape
of a mass in radiologic reports is generally described as round, oval, or irregular, and the
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Figure 5.4: A) Univariate analysis of the selected imaging features compared with the
pathologic finding (benign vs. malignant). We used a 2-tailed t test to evaluate the final set
of features used for classification purposes. Red to white cells show significant features at P
< 0.05 (corrected for false-discovery rate). Principal component analysis was only performed
when multiple texture features resulted from the common texture analysis method. B)
The receiver operating characteristic curve (solid line) demonstrates the performance of the
automated model using machine-learning techniques coupled with contrast-enhanced spectral
mammographic imaging features (area under the curve or AUC = 0.95). C) Across all features,
the overall model accuracy (90%), sensitivity (88%), and specificity (92%) were predominantly
contributed from texture features, with minor contributions from shape features. [Key: CC,
CranioCaudal; DOST, Discrete Orthonormal Stockwell Transform; GFB, Gabor Filter Banks;
GLCM, Gray Level Co-occurrence Matrices; LoGHist, Laplacian-of-Gaussian Histogram;
MLO, MedioLateral Oblique; PC, Principal Component].
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margins are categorized as circumscribed, obscured, microlobulated, indistinct, or spiculated.
The positive predictive value for carcinoma of masses visible in digital mammograms with
spiculated margins is 81% and with irregular shape is 73% [157].
Lesion shape has been used previously to predict malignancy [158]. We found benign
lesions to be associated with more round shapes and malignant lesions to have more irregular
shapes. Texture features that contributed to the model included GFB features. GFB uses
filters that are capable of detecting patterns at a certain scale and orientation. Using an
exhaustive approach, we generated a high number of GFBs to maximize the possibility of
finding patterns present at any scale or orientation. We found different enhancing patterns
for the benign and malignant groups on the recombined CESM images. These patterns were
detectable via medium and high-frequency GFB features. Combining shape irregularity and
texture feature, the model reached an area under the ROC curve of 0.95, a sensitivity of
88%, and a specificity of 92% for 50 lesions.
A strength of this study is the use of a multi-parametric texture analysis approach for
feature extraction. This approach has been designed to simplify inclusion of additional
computer vision algorithms and to maximize the chance of detecting informative features. It
has been shown to be beneficial, especially when applied to multiple images with varying
contrast characteristics [17, 56]. The texture analysis methods in our package have been
previously cited in the literature in various applications, such as for classifying on magnetic
resonance imaging [159] and computed tomography of the breast [160], assessing response to
therapy [161], and predicting tumor invasion [162].
The modest sensitivity of CAD-CESM will be addressed in future models. Contrary
to the reader study, the entirety of the lesions was not provided to the texture analysis
pipeline. Regions used for texture analysis were small (ROI size: 32x32 pixels), with well
circumscribed areas within the contours. The region size therefore was constrained by the
largest available cross-sectional area across the cohort, as well as the presence of marks from
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previous biopsies on some cases. An automated approach, using the geometric center of the
lesion, placed the ROI at the center of the lesion for consistency purposes. Although this
approach to selection of the region of interest provided us with a framework for automation,
we suspect that the 2 factors (size and location of the ROIs) might have caused the false
negative cases. In future work, we aim to address these limitations by pursuing a global
lesion texture analysis approach.
Our study has some limitations. We acknowledge a high prevalence of malignancy in our
study (52%). While our result shows great promise, future plans will include a validation
study in which we will test CAD in a larger population with other disease prevalence and
preferably in images from multiple contrast enhanced mammography vendors to improve
generalizability. We also plan to include and report on how this tool compares between
variable BI-RADS breast densities. We developed a preliminary computer-aided diagnosis
tool for contrast-enhanced spectral mammography (CAD-CESM) to test whether there is
potential to reduce false positives in breast cancer screening. CESM-based texture features
complemented the lesion boundary features in predicting lesion malignancy status. The
computational model showed higher specificity and accuracy than the human reader using
BI-RADS descriptors suggesting the potential of CESM-CAD (computer aided detection)
systems to improve breast cancer detection specificity. Although the sensitivity of the model
was lower than human readers, future work will include margin assessments which may
improve sensitivity of the CAD-CESM.
While our result shows great promise, it will need to be evaluated with external validation
datasets, including more patients. We did not assess the impact of contouring variability on
the model accuracy. In future work, we intend to implement automatic lesion segmentation
to eliminate any reader bias in drawing the ROI. Also, we did not include lesion margin
descriptors in this preliminary study. Earlier reader studies have shown a negative predictive
value of 80% to 84% for circumscribed masses and a positive predictive value of 90% to 93%
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for noncircumscribed masses [163]. In the future, we intend to extend our image analytics
package to include margin descriptors, which we hope will improve sensitivity of the model.
5.7 Conclusion
We developed a preliminary computer-aided diagnosis tool for contrast-enhanced spectral
mammography (CAD-CESM) to test whether there was potential to reduce false-positives in
breast cancer screening. CESM-based texture features complemented the lesion boundary
features in predicting malignancy status of the lesion. The computational model showed
higher specificity and accuracy than the human readers using BI-RADS descriptors, suggesting
the potential of CAD-CESM (computer aided detection) systems to improve breast cancer
detection specificity. Although the sensitivity of the model was lower than that of the human
readers, future work will include margin assessments, which may improve the sensitivity of
the CAD-CESM.
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Chapter 6
VALIDATION STUDY III: COMPUTED TOMOGRAPHY BASED TEXTURE
ANALYSIS TO DETERMINE HUMAN PAPILLOMAVIRUS STATUS OF
OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
6.1 Summary
This chapter reports on a retrospective study to determine whether machine learning
can accurately classify human papillomavirus (HPV) status of oropharyngeal squamous cell
carcinoma (OPSCC) using computed tomography (CT)-based image features. This work has
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6.2 Abstract
Objective: To determine whether machine learning can accurately classify human
papillomavirus (HPV) status of oropharyngeal squamous cell carcinoma (OPSCC) using
computed tomography (CT)-based texture analysis.
Methods: Texture analyses were retrospectively applied to regions of interest from
OPSCC primary tumors on contrast-enhanced neck CT, and machine learning was used to
create a model that classified HPV status with the highest accuracy. Results were compared
against the blinded review of 2 neuroradiologists.
Results: The HPV-positive (n = 92) and -negative (n=15) cohorts were well-matched
clinically. Neuroradiologist classification accuracies for HPV status (44.9%, 55.1%) were
not significantly different (P = 0.13), and there was a lack of agreement between the two
neuroradiologists (kappa = -0.145). The best machine learning model had an accuracy of
75.7%, which was greater than either neuroradiologist (P<0.001, P = 0.002).
Conclusions: Useful diagnostic information regarding HPV infection can be extracted
from the CT appearance of OPSCC beyond what is apparent to the trained human eye.
Keywords: Squamous cell carcinoma; human papilloma virus; oropharynx; oropharyn-
geal cancer; texture analysis; machine learning; radiomics
6.3 Introduction
Infection with high risk human papillomavirus (HPV), particularly HPV16, has become
increasingly recognized as a risk factor for oropharyngeal squamous cell carcinoma (OPSCC),
and the prevalence of HPV-positive OPSCC has dramatically risen in recent decades [164,
165]. This represents a clinically distinct group comprised of predominantly younger male
patients, many of whom lack the typical risk factors of alcohol consumption and cigarette
smoking. Because of improved prognosis and treatment response over HPV-negative OPSCC,
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establishing HPV-positivity is clinically relevant but requires tissue sampling [166, 167].
Given the complex molecular mechanisms underlying HPV-induced carcinogenesis, HPV
infection can be determined pathologically with a variety of techniques that most commonly
focus on p16 overexpression or viral DNA detection [168, 169].
Oropharyngeal squamous cell carcinoma demonstrates significant intratumoral genomic
heterogeneity [170]. This is particularly relevant for patients undergoing primary chemora-
diation whose diagnosis may be based on limited biopsy samples, as incomplete tumor
characterization could lead to treatment resistance. The field of radiomics offers the potential
to help in this regard by identifying the spatial distribution of tumor phenotypes and geno-
types on conventional radiology images [171]. This process involves extracting mineable data
from the complex visual pattern within a biomedical image by using histogram, texture, and
higher order statistical analyses in an attempt to mathematically characterize subpatterns
and similarities (or dissimilarities). Because of the high dimensional nature of this feature
data, machine learning methodology is well suited for data analysis and classification.
Computed tomography CT-based texture analysis was previously used in OPSCC to
identify individual image feature differences based on HPV status [172]. To advance this
field, the primary aims of the current study were to determine if CT-based texture analysis
and machine learning can accurately classify the HPV status of OPSCC and to compare this
classification result to that of the neuroradiologist.
6.4 Materials and Methods
This retrospective study is compliant with the Health Insurance Portability and Account-
ability Act and was approved by the Institutional Review Board at our institution with
waiver of informed consent.
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6.4.1 Study Cohort
The pathology database was queried from January 1, 2010 through December 31, 2014 to
find adult patients (age > 18 years) who underwent surgical resection of OPSCC originating
in the tonsil or base of the tongue, and patients were excluded if the OPSCC originated
in any other oropharyngeal subsite. Subject demographic and clinical data were obtained
from the electronic medical record and included age at diagnosis, gender, subsite of tumor
origin within the oropharynx, pathologic tumor T stage [173], tumor histologic type, and
HPV-status. The HPV testing was performed as part of standard clinical care utilizing
DNA in situ hybridization, and “HPV-positive” indicates positivity for one of more of the
following high risk HPV types: 16, 18, 31, 33, or 51. The OPSCC had to be of keratinizing
or non-keratinizing histologic type, and less common squamous cell carcinoma variants such
as papillary, small cell, undifferentiated, adenosquamous, and spindle cell were excluded
[174]. Based upon review of the medical record, subjects who had any history of prior head
and neck tumor, surgery, or irradiation were also excluded. Potential subjects meeting the
above criteria were cross-referenced against the radiology information management system
to identify those subjects who had a pretreatment contrast-enhanced neck CT electronically
archived and available for review. This initial study cohort consisted of 131 HPV-positive and
23 HPV-negative subjects, which is concordant with the high rate of HPV-related OPSCC
found in our practice.
To maximize generalizability of the study results, there was no requirement for the use
of a single CT scanner type, common imaging protocol, or standardized bolus of intravenous
contrast administration. Neck CT scans were eligible for inclusion even if performed at an
outside facility and, in fact, 60 of 107 neck CT’s (56.1%) were performed before patient referral
to our institution. For inclusion, the contrast-enhanced neck CT had to include axial images
with a slice thickness ranging from 1.5 mm to 3 mm, and the images had to qualitatively be
rendered with a smooth reconstruction kernel. The pretreatment contrast-enhanced neck CT
was reviewed for each potential subject by a board-certified neuroradiologist with 11 years of
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experience. To permit reliable region of interest (ROI) assessment, it was required that the
primary oropharyngeal tumor had to be clearly discernible on CT with minimum orthogonal
measurements of 1x1 cm2 on at least one axial image, leading to the further elimination
of 22 cases (19 HPV-positive and 3 HPV-negative). Subjects for whom the primary tumor
assessment on neck CT was degraded by patient motion or beam-hardening streak artifact
were also excluded (17 HPV-positive, 4 HPV-negative). Lastly, tumors containing any air
due to ulceration were removed (3 HPV-positive, 1 HPV-negative). The final subject cohort
therefore consisted of 107 cases, 92 HPV-positive and 15 HPV-negative cases, whose neck
CT scans were then anonymized to undergo texture analysis in a blinded fashion.
6.4.2 Texture Analysis
The DICOM imaging data was imported into OsiriX (version 6.5; Pixmeo SARL, Bernex,
Switzerland) and, to account for differences in imaging protocols, the images were resampled
to have uniform 0.7mm x 0.7 mm pixel spacing and 512x512 matrix size. Because ROI
assessment was performed by the same neuroradiologist who screened the neck CT’s for study
eligibility, a period of two months was allowed to elapse between CT anonymization and
further imaging evaluation to preserve blinding and eliminate potential bias. For descriptive
purposes, tumor margins were manually traced on all axial images, and tumor volume was
estimated by the “ROI Volume” function in OsiriX. In order to follow a standard approach,
the axial image with the largest tumor cross-sectional area was selected for each subject
as the basis for texture analysis. The neuroradiologist then inserted the largest possible
rectangular ROI that would fit within the margins of each tumor (Figure 6.1, b). To avoid the
potentially confounding effect of oversampling larger tumors, an automated script determined
the largest common square ROI that would fit within the borders of the manually placed
rectangular ROIs for all 107 cases. This least-common square ROI, which was found to be
16x16 pixels, was automatically centered within each respective rectangular ROI and served
as the input for two-dimensional texture analysis.
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(a) A 55 year-old man with HPV-negative squa-
mous cell carcinoma of the left palatine tonsil
(T2N1M0).
(b) A 70 year-old man with HPV-positive squa-
mous cell carcinoma of the left palatine tonsil
(T2N0M0).
Figure 6.1: Regions of interest for texture analysis. White boxes represent the largest
manually drawn rectangular ROI that would fit within the confines of the tumor. The inset
images in the upper left corner of each image are the 16x16 matrices obtained from the
isocenter of the manually drawn ROI and served as the input for 2-dimensional texture
analysis.
The texture operators used in this study have been previously described [17, 56] and
include first-order textural features, second-order Ggray Level Co-occurrence Matrices
(GLCM)[126], Laplacian of Gaussian Histogram (LoGHist)[94], Discrete Orthonormal Stock-
well Transform (DOST)[91], Gabor Filter Banks (GFB)[93], and Local Binary Patterns
(LBP)[127], summing up to a total of 77 features per patient that were exported for lesion
classification. The texture analyses were implemented in Python programming language
using custom written code based on these previous publications and open source libraries.
First, mean, standard deviation, and range of the gray level values across the ROI in
the original image (i.e. ’raw’ features) were reported as the first order statistics of texture.
Next, the gray value dynamic range of the ROI was reduced to 8 bits per pixel intensity
levels for computational feasibility of analysis. GLCM is a well-established statistical method
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of extracting second-order statistics of texture [126]. GLCM features such as entropy,
energy, angular second moment, homogeneity, dissimilarity, and correlation are descriptors
of randomness/orderliness, homogeneity, or dependency of gray-tones of the ROI to each
other. GLCM features corresponding to a distance of one pixel and four angles (0◦, 45◦,
90◦, and 135◦) were calculated. Mean and range of each feature over the four directions
were calculated and exported for a total of 26 GLCM features. The LBP method finds the
most frequent intensity patterns within a certain radius of each pixel in the ROI [127], and a
radius of three pixels was selected to focus on medium textures for a total of 12 features per
sub image.
Transform-based texture analyses such as DOST, LoGHist, and GFB capture the spectral
composition of the lesion in intermediate scales not accessible to first and second order
statistical methods. DOST is a rotationally-invariant multi-resolution spatial-frequency
representation of an image based on dyadic sampling of Fourier representation of the image
[91], while LoGHist uses different sizes of band-pass filters to highlight and enhance different
scales of texture ranging from fine to coarse details [94]. Gaussians with three different values
of sigma (2.0, 4.0 and 6.0) were used to cover the range of fine to medium scale textures.
The GFB method uses localized filters to capture details in various frequency resolutions
[93]. Using two levels of sigma (1.0 and 3.0) and two levels of frequency (0.6 and 1.0), four
different Gabor filters were applied with mean and standard deviation of the filtering result
determined. In total, 10 DOST, 18 LoGHist, and 8 GFB features were calculated, yielding a
total of 36 spectral texture features per sub image.
6.4.3 Neuroradiologist Qualitative Classification
In order for texture analysis to become a useful tool to assist with clinical image
interpretation, it needs to detect tumor characteristics not well appreciated by radiologists.
Although differences have been described between HPV-positive and HPV-negative OPSCC,
these were related to features, such as muscle invasion, exophytic morphology, and cystic
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nodal metastases [175, 176]. To date, no qualitative features (i.e. necrosis or enhancement
pattern) limited to the internal tumor appearance have been reported as a predictor of HPV
status in OPSCC [175]. To determine if texture analysis could provide useful information
beyond what was obvious to the trained human eye, two board-certified neuroradiologists,
with 25 and 28 years of experience, respectively, reviewed the tumors for all 107 subjects in
a blinded fashion. Using OsiriX, they independently assessed the primary tumors with any
window, level, and magnification adjustments that they deemed necessary and subsequently
rendered an opinion of HPV-positive or -negative for each case. Of note, the CT images were
zero-filled outside of the ROIs that had been manually traced around the tumor margins
thereby preventing ancillary features such as tumor location, invasive behavior, and cystic
metastatic lymph nodes from being taken into account. This was performed to allow an
isolated comparison based exclusively on the internal appearance of the tumor, because this
was the only aspect being interrogated with texture analysis. Again, because no differentiating
features have been published in this regard, the neuroradiologists were not given any explicit
guidelines on image review, other than to use their best judgment based on decades of
experience in head and neck radiology.
6.4.4 Machine Learning and Statistical Analysis
Open-source statistical R software (http://www.R-project.org) was used to perform
the analyses. Classification of OPSCC HPV status was achieved using widely accepted
machine learning methodology, which was performed utilizing the open-source python-based
package scikit-learn [102] in conjunction with custom written code. The texture features were
first standardized by removing the mean and standard deviation and scaling them to unit
variance. Principal component analysis (PCA) was used to improve model generalizability
to unseen cases and to reduce data dimension [177–179]. Principal component analysis
creates principal components (PCs), which are linear combinations of lesion features that
best explain the variability in the dataset. To aid with clinical interpretation, PC sets were
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constructed from each texture analysis algorithm separately resulting in 5 sets of PCs. One to
3 PCs per subset, sufficient to describe 90% of the subset variability, were selected for further
processing. Several comparative datasets were generated with PCA to find the optimal level
of variance in the PCs for gaining the highest accuracy while avoiding over-fitting. The
resulting PCs were then merged with raw first order features as the final set predictors in
the analysis. HPV status was used as the class label for supervised machine learning.
Figure 6.2: Univariate comparison of texture features, which are adjusted for multiple
comparisons using the False Discovery Rate, are plotted for comparison of texture features
between HPV-positive and -negative OPSCC tumors using the two sample t test.
Based on prevalence within our practice, there was a domain-specific reason for dataset
skewness towards the HPV-positive class. With 86% HPV-positive samples, imbalanced
class distributions rendered standard machine learning algorithms unsuitable. Instead, a
sampling approach was used to ensure that the training model had the opportunity to learn
the inherent properties of each class without the dominance of the majority class [180, 181].
An algorithm was designed that utilized a leave one out cross validation technique combined
with ensemble down-sampling. In each round, one sample was selected and set aside as the
test sample, while the remaining samples were used for training. The majority class was
split into 6 randomly selected non-overlapping subsets with sizes roughly matching that of
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the minority class. Each of these subsets together with the minority class was used to train
a classifier, rounding up to a total of 6 classifiers per test sample. The class label for the
training task was HPV status. Diagonal quadratic discriminant analysis, which was used
to perform supervised classification for each batch of samples [133, 182], is a parsimonious
model that avoids overfitting and has elicited good performance for high dimensional data
with small sample sizes [183–185]. The setting used for quadratic discriminant analysis was
no priors on classes and threshold of 0.0001 for rank estimation.
Table 6.1: Subject Demographics and Tumor Features
HPV-Positive HPV-Negative P Value
(n = 92) (n = 15)
Gender 0.66a
Male 86 (93.5%) 14 (93.3%)
Female 6 (6.5%) 1 (6.7%)
Age 54.6 ± 9.1 65.7± 13.4 0.007b
Squamous Cell Carcinoma Histology < 0.001a
Keratinizing 11 (12.0%) 12 (80.0%)
Non-keratinizing 81 (88.0%) 3 (20%)
Oropharyngeal Subsite of Tumor Origin 0.48c
Base of the Tongue 40 (43.5%) 8 (53.3%)
Tonsil 52 (56.5%) 7 (46.7%)
Tumor Volume 19.5 ± 13.4 cm3 23.0 ± 17.9 cm3 0.38b
Tumor T Stage 0.91d
T1 10 (10.9%) 1 (6.7%)
T2 36 (39.1%) 7 (46.7%)
T3 15 (16.3%) 3 (20.0%)
T4 31 (33.7%) 4 (26.7%)
Age and tumor volume are presented as mean ± standard deviation. All other values are numbers
of subjects in each category with percentages included as parentheticals. The reported P values
represent comparisons using the Fisher exact testa, two sample t testb, Pearson chi-square testc
, and the Freeman-Halton extension of the Fisher exact testd.
Tumor T stage reflects the American Joint Committee on Cancer staging system (7th edition) [173],
which was in effect during the study period.
Selecting features for classifier construction is an important issue in the machine learning
process. The sequential forward feature selection algorithm was utilized, as this selects
features that have minimal redundancy yet are maximally relevant for prediction. PCs were
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selected if they improved the classifier’s performance by at least 5%, as estimated using leave
one out cross validation [45]. After training, the 6 models were used to predict HPV status in
the test sample using the average posterior probability of the models as the final prediction.
Receiver operating characteristic curves were used to evaluate classification performance
metrics with a higher percentage of the area under the curve indicative of better model
performance.
Additional statistical analyses were performed to assess for potential differences between
the OPSCC HPV-positive and -negative groups. Differences in mean age and tumor volume
were assessed using the 2-sample t test. Frequencies for gender and tumor histologic type
were compared using the Fisher exact test, while the Pearson chi-square test was employed
for tumor subsite (i.e. base of the tongue versus tonsil). Tumor T stage frequencies were
evaluated using the Freeman-Halton extension of the Fisher exact test. The 2-sample t test
was used for a univariate comparison of texture features between HPV-positive and -negative
tumors prior to model development, and P values were corrected for multiple comparisons
using the False Discovery Rate [186]. Cohen’s κ coefficient was calculated to measure inter-
rater agreement for the prediction of HPV status by the 2 blinded neuroradiologists, while
potential differences in accuracy were assessed with a 2-tailed test of population proportion.
All hypothesis tests were 2-sided, and statistical significance was defined as P less than 0.05.
6.5 Results
6.5.1 Study Cohort
Demographic and tumor characteristics are summarized in Table 6.1. The HPV-positive
and -negative cohorts were similarly male predominant, while the subjects with HPV-positive
tumors were significantly younger on average. No statistically significant differences were
identified for tumor volume, T stage, or oropharyngeal subsite of tumor origin based on
HPV status. Concordant with previous publications, conventional keratinizing squamous
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Table 6.2: Diagnostic Performance of Texture Analysis With Machine Learning Compared
With Neuroradiologist Review for the Differentiation of HPV-Positive from HPV-Negative
OPSCC
In-Situ Hybridization
HPV-positive HPV-negative
(n = 92) (n = 15)
Texture Analysis (Diagonal
Quadratic Discriminant Analysis)
Accuracy ab75.7%
HPV-positive 69 3 Sensitivity 75.0%
Specificity 80.0%
HPV-negative 23 12 PPV 95.8%
NPV 34.3%
Neuroradiologist #1
Accuracy ac44.9%a
HPV-positive 44 11 Sensitivity 47.8%
Specificity 26.7%
HPV-negative 48 4 PPV 80.0%
NPV 7.7%
Neuroradiologist #2
Accuracy bc55.1%
HPV-positive 53 9 Sensitivity 57.6%
Specificity 40.0%
HPV-negative 39 6 PPV 85.5%
NPV 13.3%
Comparison of accuracies was performed using a 2-tailed test of population proportion:
aP < 0.001, bP = 0.002, cP = 0.13.
PPV indicates positive predictive value; NPV, negative predictive value.
cell carcinoma predominated in HPV-negative OPSCC, while the majority of HPV-positive
tumors were non-keratinizing [174].
6.5.2 Neuroradiologist Qualitative Classification
Neuroradiologist classification results for tumor HPV status are documented in Table 6.2.
The respective accuracies of 44.9% and 55.1% were not significantly different (P = 0.13).
The percent agreement between the 2 raters was 43.0%, while the κ statistic was -0.145
indicating a lack of agreement between the 2 neuroradiologists.
84
Figure 6.3: Model performance depicted by receiver operating characteristic curve. Classifiers
were trained to predict tumor HPV status, and average posterior probability of models
was used as the prediction for each classifier. Area under the curve for the best diagonal
quadratic discriminant analysis model was 0.80.
6.5.3 Texture Analysis and Machine Learning
Based on a univariate comparison, all forms of texture analysis had at least some features
that were significantly different between HPV-positive and -negative OPSCC (P < 0.05),
except for LoGHist and LBP (Figure 6.2). The performance of the best diagonal quadratic
discriminant analysis model is depicted by the receiver operating characteristic curve in
Figure 6.3, which had an area under the curve of 0.80. The model was comprised of texture
features with the highest predictive value for classification of HPV status. Figure 6.4 shows
how different texture analysis methods compare in terms of their relative contribution to
accuracy across all models, with the raw features contributing the least. The best-performing
model from diagonal quadratic discriminant analysis was significantly more accurate as
compared to the performance of either neuroradiologist (Table 6.2).
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Figure 6.4: Comparison of predictive value among texture analysis methods. As detailed
in the materials and methods, numerous models were created in an iterative fashion using
leave one out cross validation. Boxplots were generated using the statistics of all models
to summarize relative contributions to accuracy of the various texture analyses. Individual
outliers are plotted with the accuracy gained by the raw features.
6.6 Discussion
The potential for CT-based texture analysis to determine HPV status of squamous cell
carcinoma both within and outside of the oropharynx has been recently demonstrated [172,
187]. In applying a Student t test for independent samples, the authors assessed mean
differences in histogram, GLCM, gray level run length, gray level gradient matrix, and
Law features. For OPSCC, a limited number of statistically significant differences were
identified in histogram parameters (median and entropy) and GLCM entropy [172]. To
show potential future clinical applicability, the current study applied a more sophisticated
battery of texture analyses to OPSCC and synthesized these results using a machine-learning
model in lieu of simply attempting to show statistical differences for individual features. The
best classification model demonstrated a promising result of 80% area under the receiver
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operating characteristic curve. Based on the inaccurate results from the neuroradiologist
review and the lack of interobserver agreement, the difference between HPV-positive and
HPV-negative tumors is not obvious to the trained eye of an experienced neuroradiologist
when solely evaluating the intrinsic appearance of the primary tumor. Hence, although the
machine-learning classification accuracy was not perfect, it underscores that texture analysis
has the potential to complement the interpretative skills of a neuroradiologist for determining
HPV status of OPSCC. In addition, these results show promise for the generalizability of
CT-based texture analysis for OPSCC since CT scans were not acquired with a standard
imaging protocol at a single institution, in contrast to previous studies [172, 187]. This is
reassuring in light of results showing the impact that CT parameter variation can have on
texture features [188, 189].
It is well recognized that HPV-related OPSCC is a molecularly and morphologically
distinct tumor type, with the majority demonstrating a poorly differentiated, basaloid, and
non-keratinizing histologic appearance [174]. The presence of cystic lymph node metastases
from OPSCC is strongly correlated with HPV positivity [175, 176] However, the imaging
appearance of the primary tumor has historically been considered a less reliable predictor.
Cantrell and colleagues [175] found that HPV-negative tumors were significantly more likely
to invade adjacent muscle, while increased enhancement, exophytic morphology, and well
defined borders were found more frequently in HPV-positive cases, but these observed
differences did not all reach statistical significance at the P less than 0.05 level. The low
accuracy from the neuroradiologist review in the current study further supports that it
is challenging to predict HPV status of OPSCC based solely on the appearance of the
primary tumor (i.e. without taking tumor margins and cystic nodal metastases into account).
However, there is evidence that HPV-positive and -negative tumors have differences that
can be objectively quantified with imaging.
In using immunohistochemistry to identify p16 overexpression as a surrogate marker
for HPV infection, mean and minimum apparent diffusion coefficients were significantly
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lower in p16-positive OPSCC [190]. By applying cut-off values of 1.027 x 10-3 mm2/s and
0.641 x 10-3 mm2/s for mean and minimum apparent diffusion coefficients respectively, p16
status was predicted with 80.77% accuracy in a small retrospective cohort. These results are
presumably related to differences in tumor cellularity and water content and likely reflect
underlying histology. The p16-negative cohort was comprised of 64.3% keratinizing tumors,
while the p16-positive group was 66.7% non-keratinizing. However, no subgroup analysis was
reported to determine if diffusion characteristics correlated with histologic type, independent
of p16 expression.
Previous studies have shown the potential for texture analysis to extract other clinically
relevant features from imaging data in patients with OPSCC. Zhang and colleagues [191]
performed CT histogram and texture measurements in a cohort of 72 patients with locally
advanced head and neck squamous cell carcinoma, of which 40% were OPSCC. Primary
mass entropy (pixel complexity or irregularity in space) and skewness of the pixel intensity
distribution were independently associated with overall survival in patients treated with
induction chemotherapy. Unfortunately, HPV status was not available for most of their
patients, histologic data was not presented, and their Cox proportional hazards models were
not adjusted for primary mass location. As a result, it is not possible to delineate whether
the impact of these texture and histogram features on improved survival could be partially or
completely attributed to the better prognosis of HPV-related OPSCC, which is known to be
more responsive to chemoradiation, have lower recurrence rates, and demonstrate improved
disease-specific survival [166, 167]. Likewise, an additional study used texture analysis to
predict p53 expression with 81.3% accuracy in a small cohort of patients with squamous cell
carcinoma of the oropharynx and hypopharynx, but without specific mention of p16 or HPV
status [192] Because p53 expression is not tightly coupled to HPV expression, the results are
of limited value in comparing with the current study [193].
This study is limited by its retrospective nature and, based upon patient demographics
during the study period, the HPV-negative cases were underrepresented as the minority class.
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Over-sampling and under-sampling are 2 commonly used approaches in machine learning for
dealing with class imbalance [194]. We avoided over-sampling since it can lead to excessive
copies of the minority samples and result in over-fitting. Under-sampling, on the other hand,
can discard potentially useful majority samples. To avoid this drawback, we adopted an
ensemble under-sampling strategy that has shown success in fully utilizing samples of both
classes [195–197].
Future prospective validation is necessary, and this would benefit from a much larger
sample size to determine whether texture analysis is merely detecting keratinizing versus
non-keratinizing histologic differences or some other unique feature related to HPV infection.
Lastly, this study was not intended to compare texture analysis to a neuroradiologist’s
clinical interpretive skills, as the latter synthesizes numerous additional imaging features that
were deliberately hidden from view. Instead, the study was structured solely to determine
whether the CT appearance of an OPSCC primary tumor contains imaging data that has
not yet been recognized to be of qualitative value in predicting HPV status.
In conclusion, CT texture analysis and machine learning classified the HPV status of
OPSCC with a higher accuracy than neuroradiologist review when limited to the internal
appearance of the primary tumor. This suggests that useful diagnostic information can be
extracted from the CT appearance of OPSCC above and beyond what is apparent to the
trained human eye. Consequently, this technique may have potential to complement image
interpretation by using a CT-based radiomic analysis to predict HPV-status in patients with
OPSCC, though future prospective validation is necessary.
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Chapter 7
VALIDATION STUDY IV: BRAIN MR RADIOMICS TO DIFFERENTIATE COGNITIVE
DISORDERS
7.1 Summary
This chapter reports the result of a retrospective study to investigate the utility of MRI
imaging features in capturing the subtle effects of cognitive decline on the brain. Initial
results of the work was presented at Scientific Computing with Python (SciPy) conference,
July 2015, Austin, TX. The manuscript is pending submission. My contributions to this
manuscript are 1) devising technical design of the study, 2) data selection, data gathering,
and data cleaning, 3) implementing the methods section including the image analysis process
as well as the machine learning and statistical analysis processes, 4) writing and editing the
manuscript.
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Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators
within the ADNI contributed to the design and implementation of ADNI and/or provided
data but did not participate in analysis or writing of this report. A complete listing of ADNI
investigators can be found here 1.
7.2 Abstract
Subtle and gradual changes in brain anatomy may occur years prior to cognitive im-
pairment. Radiomics can help identify these underlying pathophysiological changes via
quantitative image analyses. This study explores the utility of hippocampal texture analysis
and volumetric features to differentiate between cognitive states (cognitively normal (CN),
Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), Clinical Dementia Rating
(CDR) scores. 175 cases from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with
3T T1-weighted structural magnetic resonance (MR) images were selected. Texture and
volume features from the bilateral hippocampal area were extracted and machine learning
techniques were applied to perform binary classification using Diagonal Quadratic Discrimi-
nant Analysis (DQDA) in a leave one out cross validation approach. Area under the receiver
operating characteristic (ROC) curve (AUC), sensitivity and specificity were used to assess
model performance. Texture analysis was better able to differentiate between no impairment
and mild impairment (CN-MCI: AUC of 0.86 and CDRs 0-1: AUC of 0.95). Volumetric
features achieved a better classification between no impairment and advanced stages of
impairment (CN-AD: AUC of 0.86 and CDRs 0-2: AUC of 0.98). Brain MR radiomics may
be a promising tool for assessing early cognitive impairment, as many features are sensitive
to early AD pathology.
Keywords: Texture analysis; Alzheimer’s disease; Mild cognitive impairment; Machine
learning; Radiomics
1https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
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7.3 Introduction
The identification of where an individual lies on the cognitive continuum can lead to an
earlier diagnosis of cognitive impairment. This is important for rapid communication for
management decisions and selective pharmacologic treatment options, which may be more
responsive to treatments given at this early stage. It is possible that the current therapeutics
for Alzheimer’s disease (AD) dementia fail because the intervention is occurring too late
in the disease progression. Thus, identifying quantifiable biomarkers of disease progression
beyond a collection of cognitive symptoms is paramount.
The existence of a grey zone of cognitive impairment has been reinforced by the emerging
clinical need of something beyond the binary diagnosis of the presence or absence of AD [198].
In Alzheimer’s disease dementia, the hallmark signatures of extracellular deposits of beta
amyloid (Aβ) and intraneuronal neurofibrillary tangles (NFTs), along with neuronal injury
and synaptic loss may precede clinical manifestations by several decades, placing it on the
far end of the cognitive continuum [199, 200]. Mild cognitive impairment (MCI) falls in the
intermediate stage and is often, but not always, a transitional phase from cognitive changes
of normal aging to those typically found in AD [198, 201]. Patients with MCI constitute
a high-risk group because they develop dementia at 10-15% per year compared with the
general population at 1-2% [202]. There is no gold standard for which neuropsychological
test battery is used for diagnosis of MCI, but it is important that all the main cognitive
areas are examined; these typically include executive function, attention, language, memory
and visuospatial skills [198, 203].
Neuropsychological tests in the context of AD help stage dementia severity [204]. A
popular brief cognitive screening test to detect cognitive impairment and classify patients as
having normal cognition, MCI, or dementia is the Mini Mental State Examination (MMSE)
[205]. Staging is needed to generate homogenous or comparable patient samples, define
endpoints in clinical drug trials, and to guide pharmacologic treatment options that have
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been approved for different levels of disease severity [204, 206]. However, the use of MMSE
performance in AD clinical trials and diagnostic studies for inclusion and endpoints may
have limitations [206]. Several studies have addressed the MMSE’s large ceiling and floor
effects, sensitivity to practice effects, and general psychometric limitations [207, 208]. In
determining the correspondence between the MMSE and Clinical Dementia Rating (CDR)
scores, Perneczky et al. [204] found that MMSE lacks both accuracy in the identification of
MCI or mild AD dementia, and validity in detecting and discriminating across the various
disease stages. Clinical Dementia Rating is considered the gold standard for staging dementia
severity, has good inter-rater reliability and criterion validity, and has also been shown
to predict neuropathology [209–212]. Thus, Clinical Dementia Rating scores could be a
closer approximation to brain pathology and magnetic resonance (MR) imaging and may be
sensitive in early cognitive impairment.
Multiple pattern recognition based methods applied to structural MR images have been
developed to predict Alzheimer’s disease [9, 213, 214]. Several studies found that local
hippocampal and total brain volume are significantly reduced in AD and MCI as compared
to healthy elderly [215–219]. Hippocampal volume is the most studied structural biomarker
of AD and is used in the criteria for AD diagnosis [220]. In addition, prediction of MCI
to AD conversion has been correlated with the rate and amount of hippocampal, medial
temporal lobe, and total brain atrophy [221–223].
A current challenge is to discriminate patients who are at a very early stage of cognitive
impairment. While volumetric macro-structural correlations provide useful information,
another approach that incorporates the well-established microscopic pathological changes in
AD is texture analysis. Texture analysis focuses on deriving quantitative and reproducible
mathematical metrics from images that describe the interrelations of pixel intensities across
multiple spatial scales. Texture analysis has been used previously in the context of AD [215,
221, 224, 225]. For example, Sorensen et al. describes hippocampal texture measures that
may serve as a prognostic neuroimaging biomarker of early cognitive impairment [215, 225].
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Our group has developed a radiomics texture analysis platform that was previously used
characterize gene expression and tumor content heterogeneity of brain cancers[17, 56], and
pathology of head and neck cancer [1]. Radiomics involves the high-throughput extraction of
quantitative features that converts images into minable data. These features can be used to
build descriptive and predictive models that may reveal quantitative predictive or prognostic
associations between images and clinical outcomes [26, 171, 226]. The overall goal of this
study is to classify neuropsychological performances as they relate to subtle brain changes.
In general, we hypothesize that changes in neuropsychological functions has a morphological
counterpart, detectable via structural MRI. We hypothesize that the application of brain MR
radiomics can achieve comparable classification accuracies with volume and texture features.
Our objectives are 2-fold: 1) to differentiate between cognitive states (cognitively normal
(CN), Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), and 2) to estimate
neuropsychological performance using Clinical Dementia Rating (CDR) scores.
7.4 Methods
7.4.1 Image Dataset
We used T1 MR images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database for this study [227]. Data used in the preparation of this article were obtained from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database [228]. The ADNI was
launched in 2003 as a public-private partnership, led by Principal Investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer’s disease (AD). ADNI-1 started in October
2004 as a 5-year study, with a cohort of 200 CN, 200 MCI and 400 AD cases. We selected
cases from the shared image collection ADNI1: The patients were divided into the CN, MCI,
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and AD groups and subjected to 3T imaging at the following time points: baseline, 6, 12, 18
(MCI only), and 24 months.
7.4.2 Cognitive measures
Clinical Dementia Rating (CDR) scores is one of our classification targets as it focuses on
decline in cognitively-driven everyday function, rather than objective cognitive deficits [209].
The CDR score is obtained through semi-structured interviews of patients and informants with
the goal of evaluating the patient in six domains: memory, orientation, judgment and problem
solving, community affairs, home & hobbies, and personal care [209]. An algorithm creates
an overall rating of impairment severity: 0 (no impairment), 0.5 (questionable impairment),
1.0 (mild dementia), 2.0 (moderate dementia), or 3.0 (severe dementia). Typically, a score of
0.5 is given to individuals with a diagnosis of MCI [209, 229].
We also used the categorical division of patients into three cognitive group classifications:
cognitively normal (CN), MCI and AD. Group specific inclusion criteria are available on
ADNI’s website under the General Procedures Manual [230].
7.4.3 Patient Cohort
The initial patient selection criteria were as follows: 1) available CDR score associated
with the time of image acquisition, and 2) available 3T scanning protocol to ensure maximum
resolution for the image analysis.
We found 204 unique patients in ADNI-1 with available 3T MR images. Image data was
available for all patients at different time points ranging from baseline to month 24. Since
we were interested in predicting static cognition levels (CDR scores, cognitive groups), time
point was irrelevant and we focused on the CDR scores. To ensure unique patients across
groups, we selected one time point per patient. To maximize group sizes, we started with
finding the minority group cases first: patients who were assigned the CDR score of 2 at
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any given time. These patients were excluded from all the other groups. The process was
repeated for CDR scores 1 and 0.5. All the remaining patients not assigned to the above
groups were placed in the CDR 0 group. The group of CDR score 3 was excluded due to
small sample size. Next, we proceeded to find the 3T MR scan time points associated with
the assigned group labels for patients. The image data acquired at the selected time points
were used for analysis. 29 patients were excluded because the time point of the 3T MR
image and CDR score acquisition date did not match, which was a requisite in our selection
process. 8 patients were excluded due to image unavailability. The final sample size was 175:
67 non-impaired (CDR 0), 50 questionable (CDR 0.5), 39 mild (CDR 1) and 19 moderate
(CDR 2) cognitively impaired individuals.
Table 7.1 shows the demographic information and clinical parameters of the final cohort.
Note that to receive a diagnosis of MCI or AD, in addition to clinician judgement, intra-
individual decline must be obtained with serial cognitive measurements (multiple CDR scores
over time), or by a history of change from previously attained levels [198]. Thus, the numbers
of patients between cognitive grouping and CDR scores may differ.
Table 7.1: Demographic and Clinical Parameters
CN MCI AD
(N = 62) (N = 71) (N = 42)
Male N (%) 26 (41.9) 44 (61.9)§ 17 (40.5)
Age Mean (SD) 75.2 (4.7) 75.8 (8.5) 76.2 (8.5)
CDR 0 CDR 0.5 CDR 1 CDR 2
(N = 67) (N = 50) (N = 39) (N = 19)
Male N (%) 29 (43.3) 27 (54) 22 (56.4) 9 (47.4)
Age Mean (SD) 74.9 (5.3) 75.6 (7.3) 74.3 (8.9) 81.3 (7.6)*
[Key: CDR, clinical dementia rating; AD, Alzheimer’s disease; MCI,
mild cognitive impairment; CN, cognitively normal].
§indicates significantly higher proportion of males in the MCI group
(Pearson chi-square = 4.0704, p < 0.001), and *indicates a significantly
higher age in the CDR 2 group (student’s t test, p < 0.05).
96
7.4.4 Image preprocessing
Each MPRAGE image in ADNI database is linked with related image files which have
undergone specific image preprocessing correction steps which are described on the ADNI
website [231]. To ascertain the correction of intensity values within a single scan, we
normalized the images based on cerebrospinal fluid (CSF) intensity variance (mean and
standard deviation) [232]. Texture and volume analysis were performed using the normalized
images.
7.4.5 Regions of Interest
The bilateral hippocampal area was extracted from images in two different methods for
texture and volume analysis. For texture analysis, we manually performed 2.5D hippocampal
segmentation using the MIPAV (Medical Image Processing, Analysis, and Visualization)
application version 7.2.0 [233]. 3 sequential coronal image slices with the largest cross-
sectional views of the hippocampus tissue were selected. Unlike other views, coronal view had
a common pixel spacing across the cohort as all images were 256x256 pixels with 1.02x1.02
mm2 of pixel spacings. To minimize the inclusion of areas outside the hippocampus in the
analysis, we manually marked the left and right hippocampal area in each slice using square
16x16 pixel ROIs (Figure 7.1a). The ROIs were cropped out of each image and set aside for
further analysis.
Segmentation of hippocampi volume was performed automatically as part of volumetric
feature extraction using the online volBrain framework [234]. volBrain is a framework that
automatically segments parenchyma, brain tissues, macrostructure and subcortical structures
of provided MR images in a 3D manner. Figure 7.1b shows volBrain report for one image in
the cohort.
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Figure 7.1: Segmentation of the hippocampus in texture and volume analysis (a) Texture
analysis regions of interest: The left and right hippocampal areas are manually marked
using 16x16 pixel squares (contour in red). This process is repeated on 3 coronal slices with
the largest cross-sectional view of the hippocampus area. (b) Volume analysis region of
interest: volBrain framework automatically segments subcortical brain tissues. The image
shows overlay of segmentation result in volBrain report for one of the patients in our cohort.
Hippocampal areas, the region of interest in our analysis, are shown in orange.
7.4.6 Feature Extraction
For each patient, 6 16x16 ROIs (3 image slices x 2 hippocampi) were used as feature
extraction inputs. First, to ensure comparability of spectral content across the cohort, the
dynamic range of intensities of ROIs were normalized to 0-255. Next, each ROI was analyzed
using a texture analysis pipeline with prior success in the analysis of MR images [1, 17,
56]. Developed in Python version 2.7 [99], this in-house-developed pipeline utilizes several
available libraries [235, 236] to describe texture of a region of interest statistically and
spectrally. Texture descriptors used in this study and their settings are listed in Table 7.2.
Overall, we extracted 119 texture features for each ROI. To account for sampling variability,
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we averaged the features across each hippocampus, which resulted in a total of 238 texture
features (119 per hippocampus) per patient.
Hippocampal volumetric features were generated using VolBrain pipeline [234]. volBrain
reported 3 volumetric features for the hippocampus area including absolute volume (cm3),
relative volume (%), and asymmetry index (%). Relative volume represents the sum of
hippocampi volumes in relation to the volume of intracranial cavity. The asymmetry index
shows the difference between right and left volumes divided by their mean. We used %volume
and %asymmetry for our analysis.
Table 7.2: Texture Analysis Methods, Settings, and Number of Features for a Region of
Interest
Method Feature
Type
Details # Features
Raw intensity Statistical Mean, range, and standard deviation of the
ROI before dynamic range normalization.
3
Gray Level Co-
occurrence Matrices
(GLCM) [126]
Statistical Mean and range of 13 GLCM features in-
cluding entropy, heterogeneity, uniformity,
etc. Refer to [126] for complete list of fea-
tures.
26
Discrete Orthonormal
Stockwell Transform
(DOST) [91]
Spectral Rotationally invariant dost features for
dyadic frequency bands inside the ROI.
10
Laplacian of Gaussian
Histogram (LoGHist)
[94]
Spectral Mean, standard deviation, kurtosis, skew-
ness, entropy and uniformity of the his-
togram constructed from convolutions of
the ROI with band pass filters with sigmas:
[0.7, 0.8, 1.2, 1.7, 4.0, 6.0].
36
Local Binary Patterns
(LBP) [127]
Statistical Normalized counts of a histogram generated
from aggregated intensity patterns found
within patches with 3px radius inside the
ROI.
36
Gabor Filter Banks
(GFB) [93]
Spectral Mean and standard deviation of Filtered
ROI. Filters were Gabor filters with sigmas:
[0.7, 0.8, 1.0, 1.2, 1.7, 2.0, 2.4, 3.0], frequen-
cies: [1.0, 3.0].
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7.4.7 Statistical analysis and machine learning
Open-source statistical R software (http://www.R-project.org) and Scipy 0.18.1 pack-
age [101] in Python version 2.7 were used to perform the analyses. The area under the receiver
operating characteristic curve (AUC-ROC) was used to assess classification performance.
Estimates of P-value (0.05) and 95% confidence interval using DeLong et al. method [237]
was used to estimate ROC curve significance. Open-source statistical R software and pRoc
package [72] were used for this analysis. Statistical differences between groups were tested
using Student’s t test for age and Pearson’s chi-square test for sex. Statistical significance
level was defined as p<0.05. We performed univariate analysis to compare the difference in
texture and volume feature values for both CDR groups and cognitive groups. The p-values
of the two-sample t tests were adjusted for multiple comparisons using the Benjamini and
Hochberg False Discovery Rate (FDR) correction method [186].
We used Principle Component Analysis (PCA) [238] to reduce data dimensionality of
texture features. To ensure interpretability of the principle components, PCA was applied to
features stemming from a common texture analysis method. Several comparative datasets
were generated with PCA to find the optimal level of variance. Final set of PCs represented
90% of the variance in the original features, the optimal level of variance in the PCs that
resulted in the highest accuracy while avoiding over-fitting. Texture PCs combined with
volume features were used in supervised classification experiments using 2 label variables:
(1) cognitive groups (CN, MCI, AD); (2) CDR scores. Machine learning was conducted
utilizing the open-source python-based package scikit-learn library [102] and custom-written
script. Features were selected using Sequential Forward Feature Selection (SFFS) [238]
method. Starting from an empty set, SFFS sequentially adds features to the set if they lead
to improved accuracy beyond a pre-defined threshold. We used 5% accuracy improvement as
the threshold for adding features to the model. We used Diagonal Quadratic Discriminant
Analysis (DQDA) [238] to perform supervised classification using a leave one out cross
validation (LOOCV) approach. LOOCV uses all samples except for one as the training set
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while the left-out sample serves as the test case. This process is repeated so that every
sample in the dataset serves as the test sample. The setting used for quadratic discriminant
analysis was no priors on classes and threshold of 0.0001 for rank estimation.
We encountered class-imbalance in classification experiments that involved CDR 2.
Imbalance in class size is a well-known issue in predictive modeling in which dominance
of the majority class hinders the classifier’s ability to learn the inherent properties of each
class. To ensure generalizability of the result, we used an ensemble down-sampling approach
coupled with leave one out cross validation in these experiments. In each cross-validation
round, train sample was divided into majority and minority groups. The majority group was
then randomly divided into subsets roughly the same size as the minority group. Each of
the subsets were merged with the minority group and used to build a classification model.
Average of the probabilities of the models was used as the result of the cross validation round.
7.5 Results
The MCI group had a higher proportion of males than the CN and AD groups (Pearson
chi-square = 4.0704, p < 0.001). No significant difference was observed in gender ratio of
other groups. As expected, the age of patients in the CDR 2 group was significantly higher
than that of patients at other CDR levels. Figure 7.2 compares volume features across groups
and CDR scores. Figure 7.3 shows the univariate comparison of features across feature
groups. Features extracted from left and right hippocampi showed similar significance levels.
Increasing the level of variance included in the principle components of texture feature did
not improve the results.
7.5.1 Classification of Cognitive Groups
Figure 7.4A compares Area under the ROC curves (AUCs) of this section. Classification of
Cognitive Groups reached AUC levels of 0.89 (CI: 0.82-0.94) for CN-AD, 0.86 (CI: 0.79-0.91)
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for CN-MCI, and 0.70 (CI: 0.61-0.77) for MCI-AD classification experiments, respectively.
Table 7.3 shows the performance measures, selected features, and ROC curve analysis of
this section. All models were significant at p<0.05. Texture feature used in MCI-AD and
CN-MCI was the first principle component of Laplacian of Gaussian Histogram (LoGHist)
extracted from the left hippocampal region. %Volume was predictive of cognition only in
CN-AD models.
Figure 7.2: Comparison of boxplots for the volumetric features across cognitive groups and
CDR scores. The plot shows the distribution of the two volume features (y-axis) across
different grouping of patients: cognitive states and CDR scores (x-axis). [ %Volume shows the
sum of hippocampal volumes in relation to the volume of intracranial cavity. The asymmetry
index shows the difference between right and left hippocampal volumes divided by their
mean.]
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Figure 7.3: Heatmap of univariate analysis of features across groups. Dependent variables
are listed above columns (CDR score and cognitive group). Color maps show the False
Discovery Rate (FDR) corrected p-values of a two-sample t test. Red to white colors indicates
significance (p). [HC, Hippocampus; Dost, Discrete orthonormal Stockwell transform; GFB,
Gabor Filter Banks; GLCM, Gray level Co-occurrence Matrices; LBP, Local Binary Patterns;
LoGHist, Laplacian of Gaussian Histograms].
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Table 7.3: Classification Results for Prediction of Cognitive Groups
AUC CIb SEc Z-stats P-value Model Features
CN-MCI 0.86 (0.79, 91) 0.03 11.58 <0.0001 LoGHist and LBP PCs
of left HC
MCI-AD 0.70 (0.61,0.77) 0.05 4.16 <0.0001 LBP PC of left HC
CN-AD 0.89 (0.82, 0.94) 0.03 12.31 <0.0001 %Volume
[Key: AUC, Area Under the ROC Curve; PC, Principal Component; HC, Hippocampus;
LoGHist, Laplacian of Gaussian Histogram; LBP, Local Binary Patterns].
bBinomial exact 95% Confidence Interval for the AUC.
cStandard Error of the AUC (Delong et al. [237]).
7.5.2 Classification of Clinical Dementia Rating Scores
Figure 7.4B compares Area under the ROC curves (AUCs) of this section. Overall,
models were more successful in classification when the target groups were further apart on
the CDR spectrum. The AUC levels of the models built in this section respectively were:
0.98 (CI: 0.93-0.99) for CDRs 0-2, 0.95(CI: 0.9-0.98) for CDRs 0-1, 0.84 (CI: 0.76-0.89) for
CDRs 0-0.5, 0.73 (CI:0.61-0.83) for CDRs 0.5-2, 0.71 (CI: 0.61-0.8) for CDRs 0.5-1, and 0.56
(CI: 0.42-0.69) for CDRs 1-2. Table 7.4 presents details of models performance and statistical
analysis for this section. All models were significant except for classification model of CDR
1-2. The most predictive texture features in this classification experiment were principal
components from Discrete Orthonormal Stockwell Transform (DOST) and Gabor Filter
Banks (GFB). Similar to the previous experiment, %volume was a predictive volumetric
feature. We conducted further analysis to assess whether age accounted for relative volume
significantly differentiating between CDR 0 versus 2 in Table 7.4. When age was included in
the model, relative hippocampi volume(%) remained highly statistically significant (p=0.003)
while age was not significant (p=0.35). The AUC only slightly increased from 0.98 (model
with relative volume alone) to 0.9910 (model with relative volume and age). Note, a model
containing age by itself resulted in an AUC of only 0.785, and the addition of relative volume
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significantly improved the model fit (p<0.0001). Thus, relative volume is meaningful in
differentiating between CDR 0 and 2 above and beyond age.
Table 7.4: Classification Result for Prediction of Clinical Dementia Rating (CDR) Score
AUC CIb SEc Z-stats P-value Model Features
CDRs 0,0.5 0.84 (0.76, 89) 0.04 9.67 <0.0001 %Volume
CDRs 0.5,1 0.71 (0.61,0.8) 0.05 4.03 <0.0001 DOST PC of right HC
CDRs 1,2 0.56 (0.42, 0.69) 0.08 0.74 0.46 GFB PC of left HC
PCs from DOST, LoGHist, and
CDRs 0,1 0.95 (0.9,0.98) 0.02 22.88 <0.0001 GFB of left HC, GLCM
of right HC
CDRs 0.5,2 0.73 (0.61,0.83) 0.08 2.89 0.0038 PCs from DOST and GFB
of left HC
CDRs 0,2 0.98 (0.93,0.99) 0.01 46.5 <0.0001 %Volume
[Key: AUC, area under the ROC curve; HC, hippocampus; PC, principle component;DOST, Discrete
orthonormal Stockwell transform; GFB, Gabor Filter Banks; GLCM, Gray-Level Co-occurence
Matrices].
bBinomial exact 95% Confidence Interval for the AUC.
cStandard Error of the AUC (Delong et al. [237]).
Figure 7.4: Comparison of Area Under ROC Curves. A) Area under the ROC curves of
cognitive group classification models, B) Area under the receiver operator curve of CDR
score classification models. Error bars show the confidence interval of AUCs. [Key: CN,
control; MCI, mild cognitive impairment; AD, Alzheimer’s; CDR, clinical dementia rating;
ROC, receiver operating characteristic curve; AUC, area under curve].
105
7.6 Discussion
Despite innate difficulties in identifying MCI due to its heterogeneity, we found that
the well-established volume features and texture features had comparable classification
accuracies. In distinguishing between CDR scores, we found that texture features had a
high classification accuracy (AUC: 0.95) between no cognitive impairment (CDR 0) and
mild impairment (CDR 1). Volume had a high classification accuracy (AUC: 0.98) when
distinguishing between no impairment (CDR 0) and moderate impairment (CDR 2). It is
noteworthy that texture and volume had close accuracies. Volume features performed well
in extremes (CN-AD; CDR 0-2), and texture features generally had high accuracies earlier
in cognitive impairment (CN-MCI; CDR 0-1).
The experiment to distinguish between CDR 1 and 2 was inconclusive as AUC was
poor, not achieving statistical significance (P=0.46). The transition from mild to moderate
impairment appears to be a subtle shift without pronounced, discernable steps. While
texture features suggest that CDR scores and neuropathology may have a relationship early
in cognitive impairment, i.e. early deposition of amyloid or tau, the lack of discrimination
accuracy between CDR 1 and 2 suggests the pathological depositions may not help in
improving classification accuracy. Aisen et al. [239] posit that the terminology behind mild
and moderate AD is inaccurate, because the individual has had the disease present for many
years. The clinical staging nomenclature infers a clear distinction between various stages,
but in reality, the process progresses in a more continuous manner [239].
There are debates in the literature about what exactly texture captures. In one study,
Sorensen et al. suggested that texture captures patterns related to function of hippocampus
since it seems to have significant correlation with FDG-PET uptake [215]. The same group
also found that hippocampal texture was the most important feature in the algorithm
followed by hippocampal volume in discriminating cognitive groups [225]. In our study,
texture features contributed to both CN-MCI and MCI-AD models for classification of
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sequential stages of cognitive decline. The most comparable study to ours is by Sorensen et
al [215]. Our findings are in par with their result. However One technical difference between
our methods and Sorensen’s is in preprocessing of MR images. They resampled MR images to
have consistency in voxel size across their cohort, a necessary preprocessing step when images
are obtained from different institutes. However, resampling involves interpolation, which
changes the high spatial frequency content (fine level texture) of the image. To establish
a reliable baseline for utility of texture features, we focused our study to images with a
common voxel size. In the future, we aim to validate this result on external datasets.
Due to technical limitations of our pipeline, we did not perform 3D texture analysis
on our data. Instead, we used manual placement of fixed-sized 2-dimensional ROIs (16x16
pixels) on 3 slices with the largest cross sectional view of the hippocampus, which may
include immediate anatomical structures including the entorhinal cortex. Additionally, the
3T imaging criteria within ADNI-1 dataset was a limitation which imposed a constraint on
the sample size of our study (N = 175). However, we felt it was justified given that 3T images
tend to have higher spatial resolution and contrast-to-noise ratios than 1.5T images. As a
result, we did not partition the dataset into independent train and test sets but instead, used
leave one out cross validation for evaluation of model performance. Therefore, we cannot
claim the clinical utility of textural biomarkers introduced in this study since the models
were not tested prospectively.
7.7 Conclusion
We utilized existing resources (ADNI-1) to introduce a new application of brain MR
radiomics using texture analysis and volumetric features in the field of aging, neuropsychiatry,
and dementia. Our study findings support the use of brain MR radiomics for assessing
early cognitive impairment, as many features are sensitive to early AD pathology. With
time and finesse, brain MR radiomics may have the potential for individualized prediction
of cognitive impairment or conversion to AD, and may identify individuals at the earliest
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stage of cognitive impairment. Early identification of cases has implication in identifying a
target population for clinical intervention to delay cognitive deterioration. However, future
studies need to replicate our findings and should examine the clinical utility of image texture
features as AD biomarkers.
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Chapter 8
DISCUSSION
This thesis proposed a tool for deriving quantitative imaging features from diagnostic
imaging. For AIM I, I presented an analytical informatics-driven pipeline that can contribute
to the advancement of biomedical imaging informatics in a variety of ways. Data provided
with this pipeline can be used to enhance context-driven image interpretations to improve
diagnostic accuracies. They can also be utilized in the development of advanced applications
for computer-aided diagnosis to improve performance compared with the current clinical
standard of care.
The processes of biomarker detection and measurement need to be accurate, reproducible
and feasible over time [240–242]. Imaging biomarkers are no exception in this regard. In order
to produce reproducible and reliable imaging biomarkers standardized feature extraction
processes need to be developed. Among the criticisms to traditional quantitative image
analysis studies are that they are fragmented studies that are difficult to repeat and are
rarely validated. These studies are sometimes referred to “feature engineering” experiments,
in which models are built on too specific data using overly selective feature extraction and
analysis method. Radiomics approach addresses at least one of these criticisms by reducing
the effect of feature extraction method. Using a variety of feature extraction methods,
radiomics remains open to all possible options including widening the range of parameter
settings, leaving the decision on the value of each feature to the machine learning. By
facilitating close-to-optimal extraction of information from diagnostic imaging, radiomics
serves as a bench mark for faster standardization of feature extraction and analysis processes.
This approach also expedites standardization and technical validation of potential imaging
biomarkers. Several recent standardization studies support this argument in which the
radiomics approach was used to assess robustness and reproducibility of imaging features
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[243], to determine the significance of inter-scanner variability on imaging features [244], to
find the optimal image intensity quantization method [245], and to compare across feature
selection and classification methods [105]. This pipeline currently provides a number of
highly-cited texture analysis methods. Inclusion of additional texture analysis algorithms
and other clinically relevant quantifiers such as descriptors of lesion boundary/margin can
be potential future directions for the this pipeline.
In this pipeline, we focused on the analysis of small regions (ROIs) within larger suspicious
regions identified by experts. Focusing the analysis to a smaller-sized region limits spatial
support encroached by the texture operators and avoids mixing properties from distinct
texture classes [246]. However, in general having common-sized ROI for all patients is not
necessarily a requirement for texture analysis. This requirement in our pipeline is a restriction
imposed by the discrete orthonormal Stockwell transform, in which different sizes of ROI
leads to variance in the number and content of features. The default settings of parameters
for the texture analysis operators included here are also the result of our limited experiments
with small biomedical texture. Optimal settings of parameters for feature extraction and
optimal size of the ROIs should be addressed with rigorous examination in future studies. If
available, test-retest data are also extremely helpful, as they can help prioritize features on
the basis of their reproducibility and reliability.
In my humble opinion, parameter tuning is also a limitation imposed on classic quantitative
imaging approaches. Traditionally quantitative imaging relies on classic machine learning
approaches that require previously-crafted features for learning. In recent years deep learning
has shown excelled performance in segmentation [247–250], detection [251], diagnosis [252],
and classification [253] of tissue structures. The appeal of deep learning lies its abstract
data representations and elimination of the need for hand-crafted features. Although deep
learning requires large amount of training data with attached ground truth. Moreover, the
collective data produced overtime for rare diseases probably will never suffice for the effective
use of deep learning. Scarcity of large amount of labeled data is an obstacle that is expected
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to lead to slower adoption of deep learning approach in clinical practice. Transfer learning
[254–256], in which deep trained networks trained on very large datasets (eg. ImageNet [257])
are trained with biomedical images for a different task are often suggested as an intermediate
solution to expedite the process.
We used classic classification approaches such as support vector machines in the ex-
periments presented here. Overly specific feature selection and complicated classification
methods were avoided to reduce the potential for overfitted models, specially since we had
small datasets and no separate validation or test sets. In general the success of traditional
machine learning approach in finding meaningful features heavily depends on the data
available and the parameter setting used for machine learning. I acknowledge that the
models presented here may have potential for improvement as a result of our conservative
classification approaches. These models should be considered as “proof of concept” or “pilot”
models and should be examined for the effect of parameter setting as well as the choice of
feature selection and classification method in the future.
The current pipeline has several limitations. Firstly, we performed image analysis on 2-
dimensional (2D) images in Chapters 4-6. Two-dimensional image analysis is straightforward
to implement, yet does not allow for optimal or comprehensive image analysis, particularly
for volumetric data acquired using magnetic resonance imaging (MRI) machines or computed
tomography (CT) scanners. In the Alzheimer’s study (Chapter 7) I attempted to address
this shortcoming by performing image analysis on three slices instead of one to allow for
2.5D analysis of the regions of interest and improved sampling on image data. However,
2.5D approach has also not been without disadvantages since it results in the lose of spatial
information related to distinct local habitats. To become fully comprehensive, this pipeline
needs to allow for 3D image analysis. Hence, future directions for this pipeline should include
its refinement into a volumetric analysis tool.
The second limitation of this pipeline lies in its segmentation process. Success of a
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radiomics workflow highly relies on the result of intermediate steps such as the segmentation
process. Segmentation is of utmost importance particularly for extraction of morphological
features which heavily depend on the result of segmentation. This pipeline uses manual
segmentation (outline drawn by an expert) as the basis for the selection of a region of interest.
In breast cancer study (Chapter 5) outlines drawn by radiologists were used for computation
of quantitative morphological features. However, as previously discussed in Chapter 2 (and
also in the discussion section of Chapter 5), manual segmentation is time-consuming and
can suffer from inter- and intra-reader variability, factors that can limit the prospect of this
pipeline’s use in fully elaborated workflows and the validity and reliability of the features. In
the future, this pipeline should incorporate an automatic or a semi-automatic segmentation
system to expedite the implementation process and clinical efficiency, and to result in
objective morphology features.
Studies conducted for completion of AIM II (Chapters 4-7) assessed the utility of imaging-
derived features in diagnostic applications related to head and neck cancers, breast cancer,
and Alzheimer’s disease. These retrospective studies demonstrated that identifying imaging
traits can lead to improved diagnosis accuracy and potentially result in advancement of
diagnostic biomarker discovery. Given that the image data used in these studies was acquired
from multiple sites (with the exception of the breast cancer study), I am hopeful that
repeating these experiments on datasets acquired from other institutes would render good
results in the future. In this thesis we focused on evaluation of the utility of imaging-derived
features in diagnostic applications In cancer-related studies the performance of predictive
models was compared with that of radiologists to investigate the benefits of quantitative
image analysis to routine care. In these studies we often compared the performance of models
with human readers. It should be noted that the motivation of these comparisons was to
assess the potential utility of the pipeline to supplement radiologists’ interpretive skills in
diagnostic tasks and not to compete with them.
Chapter 5 discussed the potential utility of this technique in breast cancer screening.
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The model built on quantitative image features provided reduced number of false positives
compared to trained radiologists. The study suggested that a computer aided diagnosis
system based on quantitative image features can provide benefit in improving the accuracy of
diagnosis by providing a recommendation. This can result in reduced number of unnecessary
supplemental imaging and invasive biopsy procedures for the patients leading to reduced
cost on the health care system as well as enhancement in patient outcome. This study is
under final stages of review by European Journal of radiology.
Chapter 6 and 7 discuss the utility of this pipeline in biomedical discovery. The study
reported in chapter 6 (accepted for publication by the Journal of Computed Assisted
Tomography) showed that quantitative image features could be used to detect differences
in lesion representation of HPV-positive and HPV-negative OPSCC lesions. Provided with
the same region of interest, experienced neuroradiologists did not observe any detectable
visual difference between the two cohorts. HPV is an important factor in patient prognosis
and can only be detected via biopsies. Thus a system built on this approach can potentially
enhance the diagnosis process by providing critical information at an early stage. This study
has been accepted by the Journal of Computed Tomography in 2017 (publication details to
be defined).
Chapter 7 showed texture features can provide information when proved pathological
diagnosis does not exists. Definite diagnosis of Alzheimer’s is delayed until the disease is
fully advanced and can only be pathologically proven post-mortem. By detecting earlier
signs of cognitive decline, model based on image analysis can lead to earlier interventions in
the treatment process and improved patient management.
Imaging features can also be used along with other types of biomedical data such as
genomics and clinical data to generate multi-scale models to improve patient outcome and
survival. Bridging imaging features with other sources of clinical data can provide a path for
advancement of individualized medicine [258]. It should be emphasized that these types of
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analyses identify correlations, not causes [31]. However, these correlations can inform the
decision about whether to test for certain gene alterations in biopsy samples as well as the
choice of biopsy sites [31].
Apart from the studies presented in Chapters 4-7, we also have conducted two studies
using this pipeline that support the radiogenomics argument. In 2015 our group conducted a
study in which imaging features extracted from MRI images were used to predict the tumor
content of biopsied locations of Glioblastoma Multiforme (GBM) [17]. The model was used
to generate maps of predicted tumor content across the entire lesions. These prediction maps
showed promising result when tested against a previously unseen validation set, suggesting
the utility of a radiomics models in guiding biopsy procedures. In a followup study in 2016
image features were identified as non-invasive imaging signatures for the genomics pathways
of GBM lesions. We generated prediction maps of genomics pathways of GBM across the
entirety of lesions using models built on imaging features. The models showed promising
result on unseen validation data, suggesting a potential for characterization of regional
genetic heterogeneity in glioblastoma.
Although promising, the results presented here should not be interpreted as the perfor-
mance of an established diagnostic imaging test. Radiomics is a young discipline that will
need to undergo a slow process of standardization and characterization before it reaches
the level of reliability and reproducibility required for clinical implemented diagnostic and
therapeutic systems [240–242]. The obstacles along the way can be associated with a number
of causes, including technical complexities of identifying reliable and reproducible image
features. These features need to be portraying disease manifestation across the population
and not be the result of unrecognized confounding variable such as image acquisition. To
address this concern, radiomics investigations should be validated against external completely
unseen datasets preferably from other institutes. These studies should be conducted prospec-
tively and directed to assess imaging-pathology, imaging-molecular or imaging-genomics
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correlations [259]. Patient risk factor data (such as subject age, biology) also need to be
incorporated into radiomics as these factors can influence the image features [260].
Large standardized datasets representing the full spectrum of patients are required to
result in unbiased inferences of radiomics analyses. Initiatives such as Quantitative Imaging
Biomarkers Alliance (QIBA), sponsored by Radiological Society of North America (RSNA)
and the National Institute for Biomedical Imaging and Bioengineering [261], are among
promising steps that encourage collaboration among the stakeholders and advance the field
through provision of a consensus on imaging protocols, and the measurement accuracy of
imaging biomarkers. The Cancer Imaging Archive (TCIA) [262], Quantitative Imaging Data
Warehouse (QIDW) [263], Alzheimer’s Disease Neuroimaging Initiative (ADNI) [264] are
examples of targeted data collections that aim to generate a consensus among the stakeholders
on how to optimize, harmonize, and standardize data collection and analysis processes.
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Chapter 9
CONCLUSION
Despite major advances in computational biology, gaps still exist in our understanding of
cancer dynamics. Radiomics offer the potential for a non-invasive tool to complement existing
methods of assessing disease characteristics and behavior to enhance diagnosis, monitoring,
and prediction of response to treatment for various cancers. The field of radiomics is still
young and requires rigorous technical and clinical validation studies. As the field grows,
we can expect radiomics to bridge the gaps of knowledge and help shift medicine closer to
a fundamental genetic-based and truly personalized practice. With expanding radiomics
cohorts and feature dimensions higher prediction performance in future radiomics studies is
expected.
This thesis aimed to develop a radiomics pipeline for biomedical image analysis, and to
examine its utility in diagnostic applications. The data provided with this pipeline showed
potential in the following tasks: a) to provide incremental benefit to the neuroradiologists
in differentiating small head and neck lesions (chapter 4), b) to reduce the number of false
positives in breast cancer screening (chapter 5), c) to provide insight about the presence
of HPV in a malignant type of head and neck cancer (chapter 6) and finally, d) to detect
early signs of cognitive decline in patients with Alzheimer’s disease. These studies suggest
that converting images to quantitative data can enable improved accuracy in the diagnosis
of head and neck cancers, breast cancer, and Alzheimer’s disease. Enhancing diagnostic
accuracy results in improved patient care and patient management as well as earlier and
better-informed decisions in treatment planning. Overall, this thesis is a step forward towards
the enhancements of radiomics based clinical predictions.
The Future path for this pipeline can include conducting integrative studies that contribute
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to further advancement of imaging biomarker research. Examples are standardization studies
that assess reproducibility and reliability of imaging features over image acquisition setting,
feature extraction, and feature analysis method or validation studies that assess imaging-
pathology, imaging-molecular or imaging-genomics correlations.
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DOST: Discrete Orthonormal Stockwell Transform
GFB: Gabor Filter Banks
GLCM: Gray Level Co-occurrence Matrices
LBP: Local Binary Patterns
LoGHist: Laplacian of Gaussian Histogram
ROI: Region Of Interest
PC: Principal Component
PCA: Principal Component Analysis
SVM: Support Vector Machine
QDA: Quadratic Discriminant Analysis
DQDA: DIagonal Quadratic Discriminant Analysis
LDA: Linear Discriminant Analysis
SFFS: Sequential Forward Feature Selection
AD: Alzheimer’s Disease
ADNI: Alzheimer’s Disease Neuroimaging Initiative
CDR: Clinical Dementia Rating
MCI: Mild Cognitive Impairment
CN: Cognitively Normal
CSF: Cerebro-Spinal Fluid
IP: Inverted Papilloma
SCC: Squamous Cell Carcinoma
HPV: Human PapillomaVirus
OPSCC: OroPharyngeal Squamous Cell Carcinoma
MRI: Magnetic Resonance Imaging
CT: Computed Tomography Imaging
PET: Positron Emission Tomography
T1: axial T1-weighted MRI pulse sequence
T2: axial T2-weighted MRI pulse sequence with frequency selective fat-
suppression
T1C: axial T1-weighted post-contrast MRI pulse sequence with frequency
selective fat-suppression
CESM: Contrast-Enhanced Spectral Mammography
MLO: Mediolateral Oblique
CC: Cranial-Caudal
FN: False Negative
FP: False Positive
PPV: Positive Predictive Value
NPV: Negative Predictive Value
ROC: Receiver Operating Characteristic curve
AUC-ROC: Area Under the ROC curve
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